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ABSTRACT
The bovine MHC (BoLA) class I region has been studied mostly by serology.
The products defined by the allo-antisera were thought to be alleles of a single highly
polymorphic locus. However, studies involving the use of molecular biological and
biochemical techniques revealed the presence of a second expressed locus.
Furthermore, the use of one dimensional isoelectric focussing reveals complicated
patterns of molecules from each animal which indicates that the bovine class I
encoding region is much more complex than previously thought. The aim of this
project was to investigate the origins of the charge diversity of BoLA class I
molecules observed using 1D-IEF.
The BoLA class I molecules appear to be glycosylated at a single N-linked
position and that the carbohydrate moiety attached is of the complex type with up to
three terminal sialic acid residues. The results also indicated that phosphorylation
does not occur in class I molecules immunoprecipitated from resting bovine PBL.
Furthermore, neither modification mentioned above is responsible for the observed
charge heterogeneity. Additionally, 2D analysis of the immunoprecipitated samples
suggested that alternative splicing is unlikely to be the major contributor to the
observed complexity.
In order to investigate whether the different charge variants had different
primary sequences, peptide mapping was employed. Different BoLA charge variants
had distinct peptide maps. Animals sharing part of their serotype also show
similarities in the digestion patterns they exhibited. These experiments suggested that
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each serological specificity is composed of a number of different polypeptides that
represent the products of more than one class I locus. These results and further work
involving the visual comparison of the 1D-IEF types of different animals obtained
from immunoprecipitations with the MAb W6/32 and the different bovine allo-antisera
suggested the existence of strong linkage disequilibrium among the class I molecules
expressed by different loci in our herd. The number of different charge variants with
different peptide maps indicated that the BoLA system has at least three expressed
class I loci.
Additional studies involving the computer analysis of the available bovine class
I primary sequences revealed that the secondary structures of these sequences are
similar to those of the molecules of the HLA system. Furthermore, the number of
residues in the transmembrane region (TM) of class I molecules in locus specific, the
inspection of the BoLA sequences revealed them to cluster in three distinct groups
with 37, 36 and 35 residues in their TMs respectively. This analysis gives support to
the evidence produced in this thesis that at least three BoLA class I loci are present.
However, these programmes with the available information did not allow us to identify
locus specific structural motifs.
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The major function of the vertebrate immune system is to limit or eliminate
infectious agents. One of the fundamental aspects of the immune system is its
specificity, in that it can react to individual molecules and/or agents. Three genetically
related families of antigen-binding molecules have evolved which impart this
specificity, Immunoglobulins (Ig), the T cell receptor (TcR) and the major
histocompatibility molecules (MHC). All are surface bound glycoproteins associated
with the cells of the immune system. Ig and TcR are antigen-specific receptors for B
cells and T cells respectively and the binding of specific antigen to these molecules
results in the clonal expansion of these cells. The MHC molecules are essential
accessory molecules in the interaction of antigen with the TcR.
Within the MHC family there are two major subfamilies of molecules which
are biologically functional under normal physiological conditions. MHC class I and
MHC class II are genetically linked but structurally and functionally diverse. Although
their function is the binding of antigen and its presentation to T cells, the two types
of MHC molecules bind antigen in different cellular compartments and present those
peptides to distinct T cell populations.
One feature of MHC molecules that distinguishes them from any other family
of molecules is the considerable degree of polymorphism maintained in both classes
of molecules. Polymorphism in the MHC has a profound effect on the extent and
quality of the immune response. Most allelic variation in both types of molecules is
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found to be concentrated in the membrane distal portions, a, and for class I
molecules and a, and (3, for class II molecules. This site is functionally important for
antigen presentation, or restriction of the T cell response. More polymorphism in that
site means a better capacity to respond to a wider variety of pathogens ( for reviews
see Kappes and Strominger,1988 and Lawler et al.,1990).
1.2. THE BIOLOGICAL FUNCTION OF MHC MOLECULES:
The first function that the MHC molecules are involved in before disease
combat is the shaping of the T cell repertoire which determines the subsequent ability
to discriminate between self and non-self. In the thymus, T cells will die a
programmed death if their receptor fails to bind any ligand. The T cells are deleted
if their receptor binds to MHC plus specific peptide. The cells could, on the other
hand, be rescued from programmed death or deletion if their receptor binds to MHC
ligands in the thymic epithelium with an unknown peptide content. As a consequence
of the latter event, the cells will develop into either CD4+ or CD8+ depending on the
specificity of their TcR. The mutually exclusive expression of CD4 or CD8 genes by
the mature cells is regulated by unknown molecular events (Pardoll and Carrera,1992).
MHC molecules have a number of other important biological functions. The
first observation which drew attention to this fact was graft rejection. When a donor
expresses a determinant different from the recipient, the latter's immune system
recognises the mismatch and the graft is rejected. Both class I and class II MHC
molecules have a central part to play in this mechanism (for review see Mason and
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Morris, 1986). Direct evidence for the function of MHC molecules as restriction
elements came from the observation that when mice of various H-2 types were
injected intracerebrally with Lymphocytic Choriomeningitis Virus (LCMV), all showed
severe neurological disease seven days later. When the cytotoxic activity of their
spleen cells was tested on virus infected L-cells (a fibroblast cell line of C3H (H-2Kk)
origin) it was observed that only spleen cells carrying the same H-2 specificity had
the ability to lyse the target L-cells specifically (Zinkernagel and Doherty,1974a,b;
Doherty and Zinkemagel, 1974,1975). The combination of the concepts of MHC
restriction and antigen presentation (Shimonkeritz et al.,1983; Townsend et al.,1986),
led to the view that the MHC molecules bind processed antigen fragments, forming
ligands for TcR. In 1985 Babbitt and co-workers gave life to the above model by
demonstrating that direct binding does occur between specific antigen peptides from
hen egg lysozyme and the murine class II molecule I-A\ A similar relationship was
demonstrated between the immunogenic peptide derived from chicken ovalbumin and
the I-Ad molecule. Matzinger (1981) and Schwartz (1985) developed a model to
explain MHC restriction. In this model the TcR was postulated to interact with the
complex of a peptide bound to a particular MHC molecule, whether class I or class
II, leading to the activation of the effector cell. The T cell selected by one
combination of peptide and MHC would only be restimulated by the same or a closely
related peptide/MHC complex. The specificity of restriction would then result from
variability in the MHC molecule (polymorphism), which determines both the peptide
capable of binding and the TcR selected.
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1.3. THE STRUCTURE AND ASSEMBLY OF MHC MOLECULES:
1.3.1. The Class I Molecules:
The three dimensional structure of three human MHC class I and one murine
class I MHC molecules (HLA-A2, HLA-Aw68, HLA-B27 and H-2Kb), have been
elucidated by X-ray crystallography. The structure of the murine molecule has a high
degree of similarity to those of the HLA molecules, although individual domains can
have slightly altered dispositions (Bjorkman et. al.,1987a; Garrett et al., 1989; Madden
et ah,1991; Fremont et al.,1992; Zhang et ah,1992). A description of one of these
molecules (HLA-A2) will be given here. The mature MHC molecule (Mr 44,000) has
three external domains (o^-o^), a transmembrane domain and a cytoplasmic tail. The
external domains associate with the non-MHC encoded [^-microglobulin ((32m) (fig.l).
The 003 and (32m are proximal to the membrane and are folded into [3-sandwich
structures (resembling Ig constant domains), each composed of two antiparallel |3-
pleated sheets connected by an internal disulphide bond. One sheet has four (3-strands,
while the other sheet has three. The (X3 domain is related to p2m by a 146° rotation
followed by a 1.3nm translation along the rotation axis direction instead of the
expected 180° rotation without the translation that relates pairs of antibody domains
as shown in figure 2 (Bjorkman et al., 1987a). P2m has more extensive contacts with
the (Xj-c^ platform than does the Oj domain. This is due to the effect of the 1.3nm





A SCHEMATIC REPRESENTATION OF THE STRUCTURE OF THE
PAPAIN CLEAVED HLA-A2 MOLECULE.
The molecule is shown with membrane proximal membrane domains, a3 and P2m,
at the bottom, and the polymorphic domains a, and a2 at the top. The C-terminus of
the a3 domain indicated in the figure is the papain cleavage site. The membrane-
bound molecule extends past the cleavage point towards the membrane by another 13
amino acids. The polymorphic domains form a platform with a single eight stranded
P-pleated sheet (seen edge on), covered by a-helices.
The P-strands are shown as thick arrows in the amino and carboxyl direction, a-
helices are represented as helical ribbons. Connecting loops are depicted as thin lines.
Disulphide bonds are indicated as two connected spheres.
Reprinted with permission from Nature vol.329, pp.509; Copyright (c)
1987 Macmillan Magazines Ltd.
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To summarise, a, only interacts with P2m which in turn interacts with both
membrane distal domains forming the platform.
The tt, domain, plays an important role in the selection of antigen-specific
cells. This role arises from the unique juxtaposition of the Ig-like domains, which are
thought to be an adaptation for binding CD8, which directly interacts with a, (Garret
et al., 1989). An exposed loop involving residues 223-229 appears to be a major
contact site of the 0C3 domain with the CD8 a chain, with residue 227 having the most
effect on the binding (Salter et al., 1990; Potter et al., 1989 and Connolly et al., 1988).
Position 233 is also thought to have a direct effect on the association of (X3 with CD8,
other residues, such as 235,245 and 247 are thought to have an indirect effect on the
association (Salter et al., 1990). CD8, if inhibited by monoclonal antibodies, interferes
with the process of T-cell selection which supports the findings of Garret and co¬
workers (1989) that the domain plays a role in the selection process (Aldrich et
al.,1991).
The distal part of the MHC class I molecule is comprised of the a, and a2
domains of the heavy chain which share a common tertiary structure. Each is
composed of a four-stranded antiparallel (3-pleated sheet forming the amino-terminal
half of the domain, followed by a long a-helical region. When a, and a2 are paired
in the HLA structure, they are related by a nearly exact two-fold rotation axis (177°
rotation followed by 0.07nm translation), so that a single eight-stranded antiparallel
(3-pleated sheet is formed from the four-stranded sheets in each domain. The a-helices
then lie on top of the sheet, antiparallel to each other, their helical axis making an




LOCATION OF THE PSEUDO-SYMMETRY AXES IN THE HLA-A2
MOLECULE.
The polymorphic domains a, (red) and a2 (yellow) are related by an approximate
dyad axes of symmetry (orange arrow) so that a single eight-stranded antiparallel P-
pleated sheet (the floor of the antigen binding site) is formed. The relationship is a
rotation of approximately 177° followed by a 0.07nm translation. Domains a3 (blue)
and P2m (purple) are related by 146° rotation (blue arrow) followed by a 1.3nm
translation which results in the lifting of P2m to support the platform formed by the
polymorphic domains. The two axes do not intersect, and deviate from colinearity by
25° (in projection).
Reprinted with permission from Nature vol.329,pp.509; Copyright (c)
1987 Macmillan Magazines Ltd..
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The helical regions of both the a, and (Xj domains are composed of two a-
helices. The first helix in a, is a short helix of 1.5 turns that meets a longer helix of
7.5-8 turns at an angle of approximately 110°. The domain's helical region also
starts with a short helix (3 turns) that meets a longer helix of about 7.5 turns at an
approximate angle of 130°. The short helices at the amino-termini of the helical
regions in a, and a2 form the means by which the p-pleated sheet (floor of the
domain) is linked to the top of the domain (the long helices). The long helices of these
two domains are of 4.1nm and 3.7nm respectively, and are located 1.8nm apart. The
mean interaxial distance for two helices placed next to each other is (approximately)
lnm (the peptide binding groove). The axes of the two long helices make an angle of
approximately 20 with respect to each other, so that the amino-terminal residues of
these helices project to the highest point of the molecule, and may therefore be the
accessible residues to the TcR recognising the top surface of the peptide/MHC
complex (Bjorkman etal.,1987a). The peptide binding groove is a gap around 2.5nm
deep. The sides of the gap are formed from the side chains of the two long a-helices
of the a! and OC2. The bottom is formed from side chains of the central (3-strands of
the cq-o^ P-sheet. The groove is located on the top surface of the molecule, it is lined
with both polar and non-polar side chains several of which could be critical for T cell
recognition. Figure 3 shows a peptide in the groove (Bjorkman et al.,1987b). The
assembly of class I molecules occurs in the endoplasmic reticulum (ER). Both class
I subunits (heavy chain and P2m) are guided to the ER by classical amino-terminal
signal sequences which are cleaved off once the molecules have been co-




VAN PER WAALS SURFACE REPRESENTATION OF THE ANTIGEN
RECOGNITION SITE AT THE TOP OF THE HLA-A2 MOLECULE.
The peptide binding site is a gap around 2.5nm deep and approximately l.8nm wide.
The sides of the gap are formed by the side chains of the two long a-helices of a, and
a2 domains. The bottom is formedfrom side chains of the central (3-strands of the ar
a2 (3-sheet.
Reprinted with permission from Nature vol.329, pp509; Copyright (c) 1987
Macmillan Magazines Ltd..
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Experiments with cell lines lacking P2m (Pleogh et al.,1979; Koller et al.,1990; Zijlstra
et al.,1990), indicated that these cells lack class I expression as well as CD8+ T cells.
Class I heavy chains that dissociate from P2m at the cell surface readily acquire p2m
from the surrounding medium pointing to the stabilising role played by p2m (Rock et
al.,1991; Vitiello et al.,1990 and Hansen et ah, 1988). Some exceptions are H-2Db and
H-2Ld molecules which do not require P2m for their transport and subsequent surface
expression, although its presence may still influence the conformation and increase the
stability of expression of these molecules (Krangel et al.,1979; Allen et ah, 1986;
Myers et al.,1989 and Williams et ah,1989). Until recently, however, it has been
generally assumed that MHC class I heavy chains cannot be transported to the cell
surface in a form that can be recognised as antigen-presenting molecules in the
absence of P2m. Glas and co-workers (1992) reported that cells deficient in P2m can
present major and minor histocompatibility antigen epitopes for CD8+ T cells and their
precursors. The interpretation of these results was that a fraction of MHC class I
chains can be transported to the cell surface without P2m, either alone or in association
with short peptides. These heavy chains fall below the threshold for a clear signal in
antibody binding assays and usually also below the threshold for recognition by CD8+
T cells induced by MHC class I-positive stimulator cells. However, they are sufficient
to trigger certain T-cell clones in the afferent phase of the response, at least in vivo.
These clones expand and are able to recognise heavy chains (with or without antigenic
peptide) in P2m" cells also in the effector phase. This interpretation is in line with the
notion that as few as 200 MHC-antigen ligands per cell are enough for detection by
T cell (Rosemary-Christinck et al.,1991). Townsend and co-workers (1989) used a
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mutant cell line (RMA-S), which only expresses 1/20 of the number of class I
molecules on normal cells, to study the effect of antigenic peptides on the assembly
of these molecules. They reported that exposing these mutants to certain peptides
partially restores the association of the heavy chains (Db in this case) with (32m and
their expression on the cell surface. Further work, using an in vitro system suggested
that the addition of peptides to detergent extracts from these mutant cells enhances the
assembly of class I molecules. The peptides are thought to induce conformational
changes in the a! and domains of the heavy chain and their association with P2m.
This change is influenced by the concentrations of both peptide and p2m (Townsend
et al.,1990). It was found that specific short peptides, 9-10 amino acids (a.a.) in length,
can induce folding of the heavy chain in the absence of P2m. Both these short and
longer peptides (15a.a) can stabilise preformed low-affinity heterodimers (Silver et
al.,1991; Ortz-Navarrete and Hemmerling,1991). Fahnestock and co-workers (1992),
suggested that secreted empty class I molecules are both immunologically reactive and
structurally similar to peptide-carrying class I molecules. Additionally, it was reported
that a significant portion of empty class I molecules do exist at the cell surface at
physiological temperatures. However, class I molecules with peptides appeared to be
more stable than the empty molecules (Fahnestock et al., 1992). The class I molecules
are transferred to the trans-Golgi reticulum (TGR) where they are glycosylated before
their final journey to the cell surface (Parham et al.,1975). The time before the class
I molecules appear on the cell surface varies from 10-60mins depending on the
expressing locus, with HLA-B the fastest and HLA-C the slowest, these differences
follow the speed of subunit assembly of the different class I molecules (Neefjes and
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Ploeph,1988). Using cell lines that have defects in their assembly and transport of
class I molecules, it was reported that in these cells the class I molecules are recycled
between the ER and Golgi, with a steady-state distribution favouring the ER.
Morphological and subcellular fractionation evidence suggested that the class I
molecules pass through an organelle or compartment called the "cis-Golgi network"
that sorts the protein and selects those for ER retention (Hsu et al.,1991). Degan and
Williams (1991) reported that virtually all newly synthesised class I heavy chains
associate with an 88,000 protein (p88) to form a complex which is a precursor of the
mature class I molecule. This complex exists transiently (t1/2=20-45 mins.), and the
dissociation of p88 occurs at a distinct rate for each class I molecule examined. This
slow dissociation occurs mostly after association with (32m. The kinetics of p88
dissociation from the class I heterodimers correlates with the characteristic ER to
Golgi transport rate for the H-2 molecules examined, suggesting that this dissociation
step is the rate limiting step in the ER to Golgi transport. Although this step appears
to be a prerequisite for export of these molecules from the ER, other rate limiting
steps cannot be totally excluded.
1.3.2. The Class II Molecules:
The structure of this class of molecules is far from fully understood. Unlike
class I molecules, no crystal structure for class II has been produced. The structural
analysis, therefore, has depended on the available sequences for class II molecules.
These molecules exist as heterodimers of non-covalently associated chains, a (Mr
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33,000) and (3 (M,. 29,000). They have a domain structure similar to class I, but the
four domains of the class II chains are arranged on two polypeptide chains of roughly
the same size that span the membrane bilayer. The membrane-proximal domains of
each chain are immunoglobulin-like, with homology to 0C3 and p2m of class I
molecules. The N-terminal domains of the class II chains presumably contain the
binding site for antigenic peptides, and one of these domains (fJj) has weak sequence
homology to class I cq and oq (Bjorkman etal.,1987a). Because of the homology in
sequence and antigen-presenting function between class II and class I, it is proposed
that their respective three dimensional structures are similar. By imagining an
attachment of the class I a! domain to P2m, a four domain model for class II can be
produced. Such class II molecules would have a cleft between the a helices of its cq
and polymorphic Pj domains with the bottom of the cleft formed by the N-terminal
P-strands of each domain (Brown et al.,1988). Further studies on the function of
mouse class II molecules (I-A) agree with the proposed model above (Brown et
al.,1990). Class II molecules preferentially bind peptides of 13-18 a.a.. These peptides
mosdy derive from cellular proteins (self) or from proteins in the external
environment. It is suggested that if the class II molecules were to have a similar
groove to that of class I molecules, it must be open from one or either side to be able
to accommodate the lengths of peptides proposed. One end of the groove in class I
molecules is occluded by an invariant tyrosine, the other has an invariant salt bridge.
The class II molecules may have a salt bridge at one end of the groove, but the other
end has neither a potential salt bridge nor an invariant tyrosine or other bulky side
chain which could explain the longer peptides binding to them (Rudensky et al.,1991;
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Hunt et al., 1992b).
Like the class I molecules the class II molecules are assembled in the ER and
only properly assembled a(3 heterodimers leave the ER (Kvist et al.,1982; Sant et
al.,1991). During biosynthesis a third chain, called the invariant or gamma chain,
associates transiently with the aP heterodimer and is responsible for the targeting
(signal found in cytoplasmic tail) of the heterodimers to the endocytic processing
route. It is also responsible for preventing the association of class II with
immunogenic peptides in the ER. This association is not essential for the assembly and
surface expression of the heterodimer but it makes the process more efficient (Bakke
and Doberstein,1990, Lotteau et al.,1990; Teyton and Peterson,1992; Miller and
Germain, 1986; Roche and Cresswell,1990). It is argued that antigen processing mutant
cell lines such as T2 lack the characteristic stability that class II molecules usually
show in SDS solutions. The likely reason is thought to be the inability of these
molecules to associate with antigenic peptide. The isolation of class II molecules from
the T2 cell line revealed that a large proportion of them are associated with invariant
chain derived peptides, the longest of which is 23 amino acids long (positions 81-104).
Truncated peptides (by about three amino acids) from the same region were also found
to be associated with the HLA-DR3 molecule. HLA-DR3 molecules from this cell line
can be efficiently loaded with antigenic peptides by exposure to a low pH. However,
the addition of the defined class Il-associated invariant chain peptide (CLIP) inhibits
this association. Therefore, it was suggested that the CLIP may actually define the
region of the invariant chain responsible for obstructing the class II binding site
(Riberdy et al.,1992). These findings were confirmed with work on the cell line
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721.174 (Sette et al.,1992).
Roche and co-workers (1991) reported that the class II molecules are
transported from the ER in a complex consisting of three pairs of trimers (ap
hetrodimer plus invariant chain). During the transfer from the TGR to the endocytic
route the invariant chain is degraded by endosomal proteases (Blum and
Cresswell,1988; Pieters et al.,1991). The rate of breakdown of the invariant chain
determines the speed of transfer of the hetrodimer through the endocytic route and
takes 1-3 hours (Neefjes et al.,1990).
1.4. PEPTIDE PROCESSING AND PRESENTATION:
Although the response of CD8+ T cells to a variety of virus infections could
be shown to differ with various viruses, the exact nature of the molecules recognised
by the CD8+ T cells was until recently, unclear. It was thought that the CD8+ T cells
recognised foreign glycoprotein inserted alongside MHC molecules in the membrane
of the target cell (Gething et al.,1978; Koszinowski et al.,1977; Wabake-Bunoti &
Fan, 1983). However, recent advances have revealed this notion to be untrue, showing
that class I-restricted T cells recognise degraded fragments of foreign proteins which
have passed through the cytoplasm of the target cell (Townsend et al.,1985,1986;
Maryanski et al.,1986; Townsend et al., 1986). Degradation of foreign molecules into
fragments also occurs in the context of class II MHC molecules, however, this
pathway is pH dependent and therefore different from the processing pathway of class
I molecules (Unanue,1984; Grey and Chesnut,1985; Beven,1987 and Unanue and
Allen, 1987).
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The need for both class I and II molecules to present degraded protein is
consistent with the fact that both CD8+ T cells and CD4+ T cells rely on the same
gene pool for the V genes of their TcRs (Davis and Bjorkman,1988).
1.4.1. Processing of Peptides to be complexed with Class I:
Recent evidence pointing to the importance of the cytosol as the location for
the processing machinery of the class I molecules came from Moore and co-workers
(1988). In their experiments, C57BL/6 (H-2b) mice immunised against a syngeneic
tumour cell and transfected with chicken ovalbumin (OVA) cDNA gave rise to H-2Kb
restricted CD8+ T cells specific for the OVA peptide 258-276. This synthetic peptide
and CNBr fragments of OVA were able to target H-2b cells for lysis by CD8+ T cells.
On the other hand cells incubated with native OVA for up to 24hrs did not become
sensitised for recognition and lysis. However, the direct introduction of OVA into the
cytoplasm of the cells by osmotic lysis of the pinosomes brought the Kb determinant
back into action. Similar evidence implicating the cytoplasm as a "theatre of
operations" was reported by Yewdell and co-workers (1988) with work involving
directing CD8+ T cell activity against a non-infectious influenza virus. Furthermore,
the transfection of minigenes expressing only the relevant epitope resulted in
recognition of the pre-processed antigenic site by class I but not class II MHC
restricted T cells. This indicates that the native antigen is not required for transport
of the epitope into the exocytic pathway (Sweetser et al.,1989). Furthermore,
Townsend and co-workers (1986) working on the same virus reported that cells
transfected with an influenza haemagglutonin gene lacking its signal peptide are still
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lysed by CD8+ T cells. In these cells haemagglutinin is produced and degraded in the
cytoplasm. More importantly, the core glycosylation of the protein was also lacking
in the transfected cells indicating that only degraded forms of the protein enter the ER.
The use of Brefaldin A, blocks protein transport from the ER by destroying the
Golgi complex and completely abolishes the ability of target cells to present the
required epitopes for CD8+ T cells lysis. This suggests that the ER is the location
where the processed protein encounters class I molecules. These findings all raise the
question "how do the antigenic fragments get into the ER?" (Nutchtern et al.,1989).
Studies involving the use of the mutant cell line RAM-S (has 1/20 of the
normal levels of class I expression) showed that a pre-Golgi compartment is
responsible for the loading of antigenic peptide onto class I molecules. This coupling
induces a conformational change which partially restores the expression of class I
molecules. This points to the importance of the tripartite structure (heavy chain/ (32m/
peptide) for the expression of stable class I molecules at physiological temperatures
(Townsend et al.,1989). The ability of these cells to restore class I expression suggests
that they are defective in their ability to provide sufficient peptide for the association
with class I molecules, either due to a defect in the processing pathway or in the
transport of these peptides into the secretory pathway (Cerundolo et al., 1990;
Townsend et al., 1990; Elliot et ah, 1991). The study of the class II region of the MHC
in mice, rats and humans revealed the presence of two genes with limited
polymorphism that encode proteins which belong to the family of transport proteins
(Deverson et ah,1990; Trowsdale et ah,1990; Spies etah, 1990; Colonna et ah,1992).
The nomenclature of these genes and their products has now been unified across
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species as shown in table 1 (The WHO Nomenclature Committee,1992).
The transfection of mutant cell lines RAM-S and 721.134, with cDNA
encoding TAP1 and TAP2 restores the ability of these cells to express class I
molecules (Spies and DeMars,1991; Attaya et al.,1992). It is thought that TAP1 and
TAP2 form a complex spanning the ER membrane and that both of them are needed
for peptide transport. Kleijmeer and co-workers (1992) reported that the transporter
complex is indeed located in the endoplasmic reticulum and cis-Golgi with the
orientation of the ATP-binding domain in the cytosol. These findings are consistent
with the proposed transporter role. The function of peptide transport was thought to
be ATP dependent (Kelly et al.,1992; Spies et al.,1992). However, Levy and co¬
workers (1991) reported that while ATP is essential for the loading of peptide onto
class I molecules it is not needed for the translocation of peptide across the ER
membrane. In addition to the transporter genes, the class II region of the MHC is also
found to harbour two genes that encode two proteins forming part of the Low
Molecular Mass Polypeptide (LMP) complex (Monaco and McDivitt,1982, Monaco
and McDivitt,1984). This complex is thought to be involved in the proteolytic
breakdown of foreign peptides into class I binding fragments. This complex is closely
related but not identical to the proteasome, an intracellular complex which has
multiple proteolytic activities (Brown et al.,1991; Marteinez and Monaco, 1991). The
proteasome and LMP appear to share a large number of common subunits. This may
explain the ability of anti-proteasome antibody to immunoprecipitate both molecules.
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TABLE 1.1: New nomenclature of MHC encoded transporter eenes.
SPECIES TAP1 TAP2
HUMAN Y3, PSF1, RING4 Y4, PSF2, RING 11
MICE Haml Ham2
RATS mtpl mtp2
* TAP= Transporter Associated with antigen Processing.
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The possibility of direct interaction between the LMP complex and the TAP
transporter is given credibility by the fact that the two polymorphic TAP genes and
the two polymorphic genes encoding subunits of the LMP (LMP-2 and LMP-7) are
closely linked within the class II region of the MHC system (Marteinez and
Monaco,1991; Glynn et al.,1991; Kelly et ah,1991 and Cho et al.,1991). However,
Arnold and co-workers (1992) and Momburg and co-workers (1992) using the
lymphoblastoid cell lines 721.174 and T2 respectively (both of which have a deletion
in the class II region that encompasses both the TAP and LMP haplotypes) reported
that the transfection of the TAP genes into these cells is enough to restore the stable
expression of MHC class I molecules and suggested that the LMP genes were not
generally required in that pathway. However, the fact that LMP-2 and LMP-7 are both
subunits of a larger proteolytic, complex and that they and other subunits of the
proteasome/LMP complex are regulated by IFN-y, indicates that other molecules in
the complex could also have a role in the production of antigenic peptides (Yang et
al.,1992). Further, it could be argued that the absence of only two subunits (LMP-2
and LMP-7) might not affect the ability of the complex to generate antigenic peptides.
There is limited information on the proteolytic specificity of the LMP/Proteasome
complex. Dick and co-workers (1991) showed that the complex can produce amongst
others nonameric peptides which are tailored for the binding of class I molecules
(Brown et al.,1991).
More recently Henderson and co-workers (1992) extracted peptides bound to
HLA-A2.1 molecules on the antigen processing mutant cells CEMx721.174.T2 (T2).
The analysis of these peptides revealed only seven dominant sequences as opposed to
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over 200 associated with normal cells expressing HLA-A2.1. These peptides which
were derived from signal peptide domains of normal cellular proteins, were usually
larger than 9 residues, and were also associated with normal cells expressing HLA-
A2.1. These findings suggested that the proteolysis of signal peptide domains in the
ER could be a second mechanism for processing and presentation of peptides for
association with class I molecules. These results were independently confirmed by Wei
and Cresswell (1992). An overall picture of the class I proteasome-dependent
processing pathway is given in figure 4.
The production of truncated proteins as a by-product of protein or RNA
synthesis is another mechanism for generating endogenous peptides for presentation
with class I molecules. This is consistent with the observation that promoterless genes
encoding tumour specific antigens sensitize target cells for lysis by tumour specific
CD8+ T cells following the transfection of the genes into the cell (DePlaen et al.,1988;
Sibilleet al.,1990 and Szikora et al.,1990). In 1989 it was suggested by Boon and Van
Pel that another mechanism exists for the generation of endogenous antigenic peptides.
These peptides could be generated directly by the translation of very short genetic
regions. It was proposed that short genetic regions (peptons), located around the
sequence coding for the peptide, can be transcribed autonomously. The peptons would
have the length of a few hundred base pairs, thereby exceeding only by a small factor
that of the sequence coding for the peptide. Peptons would be transcribed by a
polymerase that does not require the promoter sequences initiating eukaryotic genes.
The resulting pepton-RNA would then be translated to produce a peptide that would
either bind directly to class I molecules or do so after the precise cleavage of some
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segments. As a consequence, antigenic peptides could be produced in the absence of
classical transcription of the corresponding gene and therefore in the absence of the
normal protein product of the gene (Boon and Van Pel,1989). If peptons are a major
route of entry of determinants into the class I processing pathway, then some
determinants should be derived from out-of-ffame sequences. No sequences of that
nature have been found. This evidence suggested that peptons either do not exist, or
are never created at levels sufficient to trigger a response. Such levels are only
reached from transfected DNA; they represent prematurely terminated translation
products (Yewdell and Bennink,1992).
1.4.2. The processing of peptides for the class II Pathway:
Class II MHC molecules differ in both function and distribution from class I.
It follows, therefore, that their pathways of antigen processing are also different.
It is generally accepted that the class II molecules derive their peptides
predominantly from exogenous sources, by endocytosis, and that the subsequent
degradation process is acid-dependent and occurs in the endosome or lysosome.
Zeigler and Unanue (1982) showed that neutralisation of the acidic compartments of
the processing cell using agents such as chloroquine, primaquine and NH4C1 inhibits
antigen presentation by class II but not class I MHC molecules. However, these drugs
also have an effect on the proper processing and transport of the MHC molecules
themselves and also on the morphology of the endosomes and the trans-Golgi
reticulum (Peters et al., 1991; Pieters et ah,1991; Nowell and Quaranta,1985; Neefjes




AN OVERVIEW OF THE CLASS I PROCESSING PATHWAY.
Endogenous proteins (black) are processed in the cytoplasm via a proteolytic
complex (proteasome) (green) into smaller peptides. The peptides are transported
across the ER membrane through transporter molecules (grey). In the ER (sky blue)
the peptides associate with the class I heavy chains (navy blue and red) and P2m
(yellow). The complex ofpeptideIheavy chain!{32m is then transported through golgi
vesicles (orange) to the cell surface (pink).
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To avoid such side effects Neefjes and Ploegh (1992) used the combination of
a neuraminidase protection assay, designed to measure surface appearance of
molecules in the endocytic route (Neefjes et al.,1990), with the exposure of the
isolated class II molecules to SDS at room temperature. The results suggested that
stable class II ocp dimers are formed in an endocytic compartment while en route to
the plasma membrane, but prior to appearance at the cell surface. The stabilisation of
aP dimers in SDS could result from the binding of peptide to the class II molecules
(Sadegh-Nasserei and Germain,1991; Stern and Wiley,1992). Only the newly
synthesized pool of class II molecules, not the pre-existing cell surface pool, associates
with peptides derived from internalised antigen. This excludes a major functional role
for the fraction of recycled class II molecules in presentation of unprocessed
exogenous antigen (Davidson et al., 1991).
The study of the localisation of this binding step has been fraught with
difficulties, due to the imprecise definition of the endocytic route's subdivisions.
Peters and co-workers (1991) showed an abundance of class II molecules in the late
endocytic route implicating either the endosomes or lysosomes (both part of the
endocytic route) as possible sites for the binding of class II and antigen. Furthermore,
work by the same group involving the use of double and triple labelling with early
and late endocytotic markers revealed that a lysosomal subcompartment is the most
likely location for such an interaction with large concentrations of class II molecules
present. Other evidence from work involving the use of human and mouse APCs
further supported the involvement of a late endocytic compartment in functional
antigen presentation by class II molecules (Davidson et al.,1991; Roosnek et al.,1988
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and Harding et al.,1991).
These findings contrasted those of Guagliardi and co-workers (1990) who
suggested that it is an early endosomal compartment not a late one that is responsible
for the binding process.
The involvement of class II molecules in the presentation of endogenous
peptides has also been reported where an antigen is modified such that it is retained
in the ER (Weiss and Bogen,1991; Brooks et al.,1991). Some of these antigens may
subsequently be released from the ER and degraded in the endocytic route or, as was
reported by Armstrong (1991) and Dice (1990), the peptides or proteins could be
delivered directly to the lysosome via the cytosol.
Recently, Malanti and co-workers (1992) defined two distinct pathways for the
presentation of endogenous peptides by class II molecules. The first is similar to the
class I presentation pathway using short cytosolic peptides in a TAP-dependent
fashion. This process however, is different from the class I pathway in its sensitivity
to chloroquine. In addition, its extent and efficiency is not yet known. The second
pathway is TAP-independent and may involve the delivery of larger cytosolic
molecules to an endosomal/lysosomal compartment for processing, as was suggested
previously by Jaraquamada and co-workers (1990) and Long (1992).
A process termed autophagy could also be responsible for the delivery of
endogenous peptides to class II molecules. This process permits the uptake of
cytosolic material, followed by a fusion between the autophagocytic structure and
lysosomal elements. The cytosolic proteins are then degraded and coupled to the class
II molecules for presentation. This pathway represents a flexibility in the class II
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presentation process that allows it to treat both exogenous and endogenous molecules
on equal footing (Gordon and Seglen,1988; Dunn,1990a,b).
1.4.3. Presentation of foreign peptide:
i: Class I presentation:
It was noted when comparing the x-ray crystallographic structures of HLA-A2
and HLA-Aw68 that most of the differences were concentrated in the antigen binding
cleft (Garret et al.,1989). The determination of the structure of HLA-B27 and that of
H-2Kb revealed that the cleft is occupied by a nonamer peptide (an octamer, as well
as, a nonamer was found in the cleft of the H-2Kb molecule) in an extended
conformation as seen in fig.5 (Madden et al.,1991, Fremont et al., 1992). The extended
conformation of bound peptides allows extensive hydrogen bonding with the peptide
main chain. Helical conformations, on the other hand, cannot establish the same
number of favourable intermolecular interactions because of their intramolecular
backbone hydrogen bonds (Rognan et al.,1992). Reddehase and co-workers (1989),
using a technique of systematic delimitation of an antigenic site, identified a
pentapeptide motif as the minimal antigenic determinant presented by class I
molecules and recognised by the TcR. However, nonamer peptides form more stable
and active complexes with class I molecules and it is generally accepted that peptides
8-10 residues long preferentially bind to class I molecules (Tsomides et al.,1991;




PEPTIDE BOUND TO A CLASS I MHC MOLECULE.
The carhon-a backbone of the a, and a2 domains is shown in the blue with Van der
Waals highlighting of the two a-helices (yellow). Van der Waals surface of a
hypothetical bound peptide is shown between the two helices (pink). The peptides
usually bind class I molecules in an extended conformation.
Reprinted with permission from Nature vol.334, pp.399; Copyright (c)
1988 Macmillan Magazines Ltd..
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co-workers (1992) reported that peptides of up to 11 residues can bind HLA-Aw68.
X-ray crystallography at resolution 0.19nm showed the atomic structure at the first
three and the last two a.a. with no connecting electron density. This suggested that the
bound peptides were held at both ends (P2 and the carboxyl terminal residue) and
compensate for their extra length by bulging out in the middle (Guo et al.,1992).
Silver and co-workers (1992) reported that peptide Np 91-99 of the influenza virus
nucleoprotein binds to HLA-Aw68 with the residues at either end (PI, P2, P3 and P9)
of the peptide substantially buried in the peptide binding site. The residues in the
middle of the peptide, P4-P7, make no hydrogen bonds to the HLA molecule and P4
and P5 do not even make van der Waals contacts. Eleven polymorphic MHC residues
contact PI and P2 and eight other polymorphic MHC residues contact P9, the rest of
the peptide contacts only ten MHC residues. In the area of the peptide where contact
to HLA is sparse, water molecules provide a hydrogen-bonding bridge to HLA (Silver
et al.,1992). Apart from the residues at either end of the peptide, all the other residues
are available for TcR recognition. This general mode of interaction is also seen with
HLA-B27 (Madden et al., 1991; Jardetsky et al.,.1991 and Madden et al.,1992), HLA-
Aw68 (Guo et al.,1992), HLA-A2 (Saper et al.,1991) and H-2Kb (Fremont et al.,1992
and Zhang et al.,1992). The peptides bound to the same class I molecule were found
to share sequence motifs which must complement the binding pockets in the class I
molecule in question. Each peptide motif has anchoring positions and these also vary
depending on the class I molecule involved. It was reported that these positions are
5 and 9 for H-2Db molecules, and at positions 2 and 9 for H-2Kd and HLA-A2.1
molecules or 5 (or 6) and 8 (or 9) for H-2Kb molecules. The HLA-B27 molecule has
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a binding motif that is constrained at position 2 followed by positions 1 and 9 and to
a lesser extent position 3. In addition, it was found that the C-terminal residues are
always hydrophobic. These restricted pockets in the antigen binding groove are
specific for all the members of a family of amino acids (hydrophobic, positively
charged...etc.). However, there is usually some preference for one amino acid out of
each family (Falk et al.,1991; Madden et al.,1991; Jardetsky et ah,1991; Hunt et
ah, 1992a; Fremont et al., 1992). The residues not involved in anchoring the antigenic
peptide to the groove all have the potential of being exposed enough to interact with
the TcR (Madden et al.,1991). The surface of the MHC class I molecule recognised
by the TcR is thought to be of similar size to that of a protein antigen that is
recognised by the Fab fragment of an antibody approximately 7-9nm2. This stems from
the resemblance between the TcR and the Fab fragment (Davis and Bjorkman,1988;
Clothia et ah,1988; Davies,1990). However, Fremont and co-workers (1992), working
on the H-2Kb molecule, reported that only a few of the peptide side chains are
significantly exposed after binding and in ideal situations they may only contribute
some l-3nm2 of the surface to the TcR-MHC class I interface. Thus, if the analogy
with antibodies holds true, the MHC class I molecule will constitute at least two thirds
of what the TcR recognises. A model of the peptide/MHC class I/TcR interaction is
given in Figure 6. van Bleek and Nathenson (1991) suggested that it is the
polymorphism at the antigen binding groove that exerts a selection pressure and
determines the kind of peptides that can bind to a particular class I molecule.
Furthermore, Perarnau and co-workers (1990), reported that structural polymorphism




A MODEL FOR PEPTIDE/MHC CLASS I/TcR INTERACTION.
The TcR complex (top of the figure), here represented by a Fab molecule, is bound
to an MHC/Peptide complex (bottom of the figure). The colour codes for the
MFICIPeptide complex are the same as in figure 5. In this model most of the
interaction at the interface between the two complexes is between the peptide and the
Tcr and not between the MHC molecule and the TcR as suggested by Fremont and co¬
workers (1992).
Reprinted with permission from Nature vol.334, pp.399; C >pv ight (c)
1988 Macmillan Magazines Ltd..
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Position 85 was found to be critical for peptide binding. This residue is not a
contact residue between (^m and the floor of the groove (Garret et al.,1989). The
restricting effect could arise through either intermolecular interactions between
distantly related residues or through species-associated three-dimensional
polymorphism of class I molecules. Alternatively, one might consider that the class
I molecules are flexible and can adopt configurations other than the ones identified by
crystallography which might be critical for the binding of peptide. This limited effect,
when combined with the extensive polymorphism of class I heavy chains, would result
in the significant enlargement of the species repertoire of peptides presented by class
I molecules. Mice express seven different (32m alleles, humans on the other hand
express only one (Perarnau et al.,1990). In addition to the contributions of both heavy
and light chains in selecting the peptides that would bind a particular class I molecule,
it was recently reported that polymorphism in the major histocompatibility complex-
encoded peptide transporter genes is also associated with shaping the range of bound
peptides (Powis et al.,1992).
ii: Class II presentation:
Work by Rudensky and co-workers (1991) and Hunt and co-workers (1992b)
suggested that, unlike the antigen binding groove of class I molecules, the groove of
the class II molecules could be open at one or either end to allow the accommodation
of larger peptides; 13-18 amino acids long. The ability of unrelated peptides to inhibit
the binding of one another to the same class II molecules suggests that class II
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molecules have a single peptide binding site (Buus et al.,1987). Sette and co-workers
(1988) following observations by Rothbard (1986), showed that the majority of
peptides from Ovalbumin, Myoglobin and Haemagglutonin that bind to I-Ad molecules
share a six residue region of the bound peptide that always consisted of the following
sequence for the four middle amino acids: polar (or glycine)-hydrophobic-
hydrophobic-charged (or glycine). These were HAAH, HVLH for ovalbumin and
myoglobin respectively and three of the four from Haemagglutonin were TAA. Hunt
and co-workers (1992) reported that the crucial part of the peptides binding to I-Ad is
contained within a ten-residue sequence QMVRTAAEVA. This motif determines the
capacity of a peptide to interact with a particular MHC molecule perhaps by allowing
the peptide to assume the correct conformation for binding. Further work indicated
that most peptides capable of binding I-Ad and I-Ed molecules share structural motifs
similar to the one described above. The definition of these motifs was found to be
broad, and at any given position at least three, and usually more, amino acids are
compatible with good binding. This broad spectrum of binding enables the small
number of class II specificities to bind a larger number of peptide antigens (Sette et
al.,1989; Rothbard and Taylor,1988). The inability to determine similar motifs in a
number of peptides that bind these MHC molecules was attributed to the possibility
that some of these peptides assume different conformations which might require
distinct structural motifs. Indeed, Kurata and Berzofsky (1990) reported that the same
peptide can bind the same class II molecule (in this case I-Ed) in more than one way.
They also reported that a given residue within a peptide may not have a unique
function of always interacting with the MHC molecule or TcR, but may change from
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one role to the other as it is presented to different T-cells. Despite this broad
specificity, such motifs can be used successfully to predict peptides that are capable
of interacting with a given class IId molecule. Such predictions, whether involving
class I or class II molecules, could be of considerable interest in an attempt to select
synthetic vaccine candidates to identify possible autoantigens in self molecules, and
to select strong binders to MHC molecules that might function as specific inhibitors
of MHC-associated autoimmune disease (Sette et al., 1989).
1.5. GENOMIC ORGANISATION OF THE MHC:
1.5.1. The Human and Murine MHCs (HLA and H-2):
The human MHC is located on chromosome 6 at 6p21.1 to 6p21.3 covering
a length of DNA of approximately 4Mb. It is 2-3 times the size of the H-2 system
which is located on chromosome 17 of the murine genome (Klein, 1975). The general
organisation of the different classes of MHC genes relative to each other differs in
both species. In mouse the class II and class III loci are located between the class I
loci. In the HLA system the class II region is proximal to the centromere followed by
the class III region with the class I cluster of genes closer to a telomeric position
(Howard, 1987; Trowsdale et al.,1991). The class I genes in both species constitute
a multigene family. The HLA system contains up to 20 class I genes, pseudogene and
gene fragments (Jordan et al., 1985; Kolleret al.,1987 and Srivastavaet al.,1987). The
number of class I genes present in the H-2 system ranges from 26-33 depending on
the haplotype of the animal (Steinmetz et al.,1982; Hammerling et al.,1985; Fisher et
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al.,1985 and Weiss et al., 1984). The murine class I genes are located at four encoded
loci H-2K, D, L (class la loci) and the Qa/TLa region (class lb loci). Each of these
loci is defined by serological analysis of recombinant inbred mouse strains. The K, D
and to a lesser extent L loci are highly polymorphic and are expressed on most
nucleated cells. The Qa and TLa genes are considerably less polymorphic and exhibit
a limited tissue distribution. Moreover, their encoded products have a wide range of
molecular weights ranging from 30,000-50,000 (Flaherty et al.,1990). The class la loci
in humans are HLA-A, B and C (van Rood et al.,1981). Studies by Orr and DeMars
(1983), Koller and co-workers (1989) as well as Carrol et al.(1987), Dunham et al.
(1987) and Lawrence et al.(1987), using techniques such as analysis of recombination
within informative pedigrees, induced HLA-loss mutants and, pulsed field gel
electrophoresis (PFGE), predicted that the HLA class I cluster spans approximately
2000 Kilobase (kb). The centromeric boundary being HLA-B and the telomeric
boundary not precisely defined. The HLA-B and C loci are most closely linked and
appear to be about 85 kb apart (Bronson et ah, 1991). The HLA-A locus is at the
telomeric end of the system. This subregion has a number of genes with similar
properties to genes of the Qa/TLa region of the murine MHC, namely HLA-E, F and
G. The function of these class lb molecules in both mice and humans has not been
positively identified (Kress et ah,1983; Flaherty et al.,1990). They have the potential
to carry out some of the non-immunological functions suggested for the class I
glycoproteins, including a role in adhesion (Zeleny et al.,1978), and contact inhibition
(Curtis and Rooney,1979) and expression of hormone receptors (Edidin,1988). They
might also have immunological functions as antigen presenters, it was suggested that
A
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they might act as restriction elements for invariant antigens such as the endogenously
expressed embryonal and differentiation antigens (Ostrand-Rosenberg et al., 1989).
Stress proteins marking damaged cells for possible destruction represent another class
of potential endogenous antigen (Asarnow et al.,1988). Another category is
carbohydrates, or other unusual nonpeptide antigens derived from bacteria and fungi.
During ontogeny the y8 T cells are coordinately expressed with some of the known
Qa/Tla genes. In adult mice the great majority of these cells are found in skin, gut and
lung; hence the proposed function of yd T cells and the Qa/Tla molecules function as
restriction elements in the immune responses against pathogens in these tissues
(Strominger,1989). Additionally, some class lb molecules (Qa-lb) are recognised by
aP T cells in TAP2 deficient cells indicating that they not only have the ability to
interact with these cells, but additionally that their acquisition of peptide antigen might
be TAP-independent (Aldrich et al.,1992). A recent report suggested that the molecule
Qa-2 does act as a peptide receptor with ligand specificities (similar to but more
stringent than that of class la molecules (Rotzschke et al.,1993).
The class II molecules are encoded by genes in the same complex in both
species. The HLA-D complex on chromosome 6 and the H-2I complex on
chromosome 17. This was mainly established by mapping genomic clones in cosmid
and phage vectors. These genes encode a two-subunit heterodimer with a and p
chains. It was established that related a and P genes (where both identified) lie close
to each other. Most of the a/P gene pairs are disposed tail to tail or (3'-to-3'). The DP
subregion in the HLA system is an exception with a head to head arrangement (5'-to-
5') for the a/P gene pairs (Okada et al.,1985). Three families of class II genes have
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been identified in the HLA system, HLA-DP, DQ and DR (Trowsdale et al.,1984;
Okada et al.,1985 and Gustafssen et al.,1987). However, other class 13 loci might exist.
HLA-DNA and HLA-DOB are genes encoding a and (3 chain sequences respectively,
which are different from those encoded by the DP, DQ and DR families (Trowsdale
and Kelly,1985; Inoko et al.,1985 and Tonnelle et al.,1985). The H-2I region on the
other hand has two defined gene families I-A and I-E. The I-A molecules are
considered to be homologues of the molecules encoded by the HLA-DQ genes, and
I-E being homologues to HLA-DR (both on sequence similarities) (Widera and
Flavell,1985). It was reported recently that a cluster of non-class II genes are located
centromeric to DP (Hanson et al.,1991). A series of Really Interesting Novel Genes
(RING3,6,7,12,4,9,10 and 11 respectively) lie between HLA-DNA and HLA-DOB
genes (Hanson et al., 1991; Kelly et al., 199la; Robertson, 1991; Trowsdale et al., 1991
and Glynne et al.,1991). RING3 has no obvious function in the immune system,
RINGs 6 and 7 are highly related to the class II a and (3 sequences and are candidates
to becoming the fourth and fifth class II loci HLA-DMA and DMB respectively (Kelly
et al.,1991b; Trowsdale et al.,1991b). RINGs 10 and 12 (LMP-2 and LMP-7
respectively) are thought to encode components of the antigen processing pathway for
class I molecules (Glynne et al.,1991; Kelly et al., 199lb). Finally, RINGs 4 and 11
(TAP1 and TAP2 respectively) are thought to encode the transporter molecules
involved in translocating antigenic peptides into the ER lumen in order to be coupled
to class I molecules (Kelly et al., 1992). The genomic organisation of the HLA system




THE ORGANISATION OF THE HUMAN MHC COMPLEX.
The map of the human MHC complex including the genes encoding for the class I,








D- CN [ 1































































































































































x 3P i s
91 5 '■
u. U ^ - p
t HI C •-
5-2 s n
Sci E S -£
k- —
~
p« "5. 2 c
2h
010






Reprinted with permission from Immunologytodav vol.12, pp.444-445;
Copyright (c) 1991 Elsevier Publications Ltd.
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1.5.2. The Organisation of the Bovine MHC (BoLA):
The BoLA system has been tentatively localised on the short arm of
chromosome 23 bands ql3-23 by in situ hybridisation using a cloned porcine class I
gene as a probe (Fries et al.,1986).
The class I molecules in cattle have so far only been analysed by serology
using antisera raised from calf-dam reciprocal immunisations and alloreactive
cytotoxic T-cells (Spooner et al.,1979; Oliver et al., 1981). The allo-antisera are then
absorbed against a random panel of cells to reduce their cross-reactivity, and produce
"operationally monospecific" allo-antisera that are thought to recognise a single BoLA
specificity (Spooner et al., 1980). These allo-antisera, whether against class I or class
II are then employed in microcytotoxicity assays. Operationally monospecific allo-
antisera, raised against the bovine class II molecules in BoLA class I matched animals,
are produced in much the same way as described for the class I allo-antisera, they are
however, much more laborious and time consuming to produce, with some class II
molecules appearing to be more immunogenic than others (Aniens et al.,1991;
Williams et al.,1991). According to the latest workshop, it is thought that there are
around 50 class I alleles most of which are encoded by a single highly polymorphic
class I locus termed the BoLA-A (Bernoco et al.,1991). The accuracy of the
serological typing in these workshops is assessed by the degree of agreement in
antigen detection between different laboratories. It should be noted at this point that
most of the animals tested and in the BoLA workshops have a similar genetic
background (Bos, taurus), with only 7.7% of the total number of animals in the third
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workshop representing Bos indicus and only 6.6% of the total were B. taurus * B.
indicus crosses (Bull et ah,1989). This, when coupled with the fact that most of the
allo-antisera are produced in B. taurus animals, draws the attention to the possible bias
that this may incur on the results observed.
Several monoclonal antibodies raised against class I antigens from other
species have the ability to detect non-polymorphic determinants on bovine cells
(Brodsky et al., 1981; Chardon et ah, 1983). These could be the products of less
polymorphic class la loci such as HLA-C and H-2L or the class lb products.
It was recently reported that the bovine class I MHC region is estimated to
span 1650kb, with 770kb being a minimum estimated size (Bensaid et al.,1991b). The
rare-cutter restriction enzyme Sfil cleaves the class I complex (from a single animal)
into six fragments. On the assumption that each BoLA class I gene is 5kb, and that
the probability of there being an Sfil site in any given 5kb fragment of DNA is low.
it is probable that every such fragment contains at least one class I gene as determined
by hybridisation with cDNA probes. This is exemplified by the finding that two
distinct 3'UT regions are transcribed by the same Sfil fragment of 250kb. Thus, two
tightly linked loci are present within a single fragment. These, when added to the
genes contained in the five remaining fragments gives the number of class I loci in
the bovine MHC to be at least seven. However, the number of functional loci to date
is thought to be two relying on evidence from biochemical as well as DNA sequencing
and transfection studies (Ennis et al.,1988; Toye et al.,1990; Bensaid et al.,1991a;
Joosten et ah,1992; Ellis et ah,1993). A tentative map of the BoLA class I encoding
region is given in figure 8.
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The existence of a class II encoding region in the BoLA system, BoLA-D, has
been reported by a number of groups (Spooner et al.,1978; Usinger et al., 1977).
Serological methods of studying the complex were employed but proved to have little
reproducibility (Usinger et ah,1981). The region is divided into a number of
subregions DQ, DR, DO, DZ and DY. Human probes for class I and class II genes
were used in RFLP studies to analyse bovine DNA. The results suggested that the
numbers of genes within the BoLA system are similar to that in humans, and shows
considerable polymorphism at the DNA level. The BoLA-D complex is thought to
encode one DRA and three DRB genes one of which was found to be a pseudogene
(Groenen et al.,1990), one to two DQA and DQB genes, one DZA gene, one DYA
and one DYB. A recent addition to the family was a (3-chain encoding gene called
DIB (Andersson and Rask, 1988; Andersson et al.,1988; van der Poel et al.,1990;
Stone and Muggli-Cockett, 1990). Other results by Andersson et al. (1986a,b) and
Vaiman et al. (1986) involving the use of RFLP techniques to analyse bovine genomic
DNA using human cDNA probes for the genes of the DR and DQ regions, suggested
a variability in the number of class II genes between different haplotypes. Such
polymorphism in the number of genes of the DR region has also been reported in the
HLA system (Bohem et al.,1985).
Serologically determined BoLA class I and BoLA-DQB types determined
using RFLP in Norwegian cattle showed statistically significant strong linkage




A TENTATIVE MAP OF THE BoLA CLASS I ENCODING REGION.
Class I genes that are known to encode expressed products are shown in red. Other
class I loci are shown in blue.
1xDIBZA1XDYA/2xQDRA 1xDYB/2Q3R complement BoLA-A-B 210kb
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(Vage et al.,1992). These results further augment previous reports addressing the same
question (Lindberg and Andersson,1988; Mackie and Stear,1990). Lindberg and
Andersson (1988) estimated the recombination frequency between the bovine class I
and DQ genes to be less than 6.4%, such close genetic linkage may contribute to the
linkage disequilibria observed.
General knowledge about the genomic organisation of the BoLA system falls
far short of its equivalents in humans and mice. The use of more extensive studies and
more advanced techniques is important if more progress is to be made. However, it
is a wide belief that the genetic organisation of BoLA-D and the bovine MHC in
general is closer to its human counterpart than to that of the mouse (Womack and
Moll, 1986; Skow et al.,1988; Groenen et al.,1989; Bensaid et al.,1991b).
1.6. MHC MOLECULES AND DISEASE ASSOCIATIONS:
The MHC class I and class II molecules are specific restriction molecules in
antigen presentation. Hence, the presence of a certain MHC molecule could be used
as a marker of susceptibility to different pathogens. A better understanding of these
associations would give a better chance of predicting the outcome of a disease and
will also aid the design of better therapies. A review of the most important
associations between MHC molecules and disease is given below.
1.6.1. HLA and disease:
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i. Associations with infectious disease:
The human immunodeficiency virus (HIV) has probably been the most
extensively studied pathogen in the past few years. The most striking feature of this
virus is its ability to persist regardless of the immune system of the host. A recent
study, Phillips et al. (1991) defined a single HLA-B27-restricted epitope and three
HLA-B8-restricted antigenic epitopes in HIV gag. Analysis of these epitopes revealed
that amino acid variation in HIV gag tend to accumulate in or near these CD8+ T cells
epitopes, therefore, suggesting that the site of this genetic variation in the virus would
influence the ability of the immune system to recognise it, and that this variation is
a result of selection pressure by the HLA class I haplotype. From the observation of
the relatively high frequency of HIV a.a. mutations observed in HLA-B8 patients,
compared with the HLA-B27 patients, it was suggested that the epitope presented by
this molecule (HLA-B8) tolerates variation and that such variation does not affect the
survival of the virus. The epitope presented by HLA-B27, on the other hand, does not
tolerate such variation, probably due to its structural or functional importance to the
virus. Thus, patients with HLA-B27 will always have the ability to keep the vims in
check whereas individuals with HLA-B8 will be at a disadvantage. This explanation
is supported by the observed association of the HLA-A1,B8,DR3 haplotype with poor
outcome in HIV infection. The effect of HLA-B27 is not known. HLA-B8 is relatively
common in Caucasians and could exert an effect on variability of prevalent vims
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strains.
In a case study of malaria (Plasmodium falciparum) in West African children
it was found that the presence of HLA class I type Bw53 is significantly decreased
(15.7%) among individuals with severe malaria. This was determined through
serological typing. To make sure that the association observed was not by chance,
HLA-Bw53 was isolated and cloned and a PCR dependent method of typing was
developed to study the differences in its frequency between severe cases and mild
controls. The frequency of the allele was found to be 16.9% among cases of severe
malaria and 25.4% among mild controls, an association which was statistically
significant (P=0.008) and which confirmed the results of serology. The HLA class II
haplotypes in the population were studied using restriction fragment length
polymorphism (RFLP). The haplotype DRwl3 and DQwl showed significant
differences between children with severe malarial anaemia and the mild controls. DNA
sequencing and T-cell assays revealed that the DRwl3 allele is in fact the DRB 1*1302
subtype. In common with HLA-Bw53 the frequency of this allele in severe malarial
anaemia cases is much less than in mild controls, indicating that it is a protective
rather than a susceptibility haplotype. The DRB 1*1302 was found to be linked to the
DQB 1*0501. The role of HLA-B53 in protection to severe malaria was investigated
by sequencing the peptides eluted from this molecule, followed by screening of
candidate epitopes from pre-erythrocyte-stage antigens of Plasmodium falciparum in
biochemical and cellular assays. Among malaria-immune Africans, HLA-B53 restricted
CD8+ T-cells recognise a conserved nonamer peptide from liver stage-specific antigen-
1 (LSA-1) with no restricted epitopes from other antigens (Hill et al., 1992). The class
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II molecules, on the other hand, are thought to be involved in the presentation of a
particular epitope on a blood-stage parasite antigen to CD4+ T cells, leading to more
rapid parasite clearance. This study gave the clearest evidence yet that a lethal
infectious pathogen is influencing the evolution of MHC polymorphism by selection
pressure (Hill et al., 1991).
Other studies have indicated that the persistence of several RNA and DNA
viruses in the neural cells is due to the lack of sufficient expression of class I
molecules which is essential for the proper function of CD8+ T cells in immune
surveillance mechanism responsible for identifying infected cells in the body, once
again pointing to the importance of class I presentation for the combat of such
diseases (Joly et al.,1991).
ii. Associations with autoimmune diseases:
MHC class I-associated autoimmune diseases are a small group (compared to
the class II -associated ones) and fall in two main categories: (i) the HLA-B27-related
spondyloarthropathies, including ankylosing spondylitis, Reiter's syndrome, and
reactive arthropathy, and (ii) psoriasis vulgaris, which is associated with HLA-
B13.B16 and B17.
HLA-B27 has a strong association with Ankylosing Spondylitis, particularly
in Caucasians (Yu et al., 1989). This association may be based on molecular mimicry.
Such mimicry arises through a number of amino acid and sequence homologies that
have been found between HLA molecules and putative pathogens such as Klebsiella
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pneumoniae. Consequently molecular similarities between IC pneumoniae and B27
may be important, such as the six-amino acid sequence shared between HLA-B27 (72-
77) and a segment of K. pneumoniae nitrogenase (188-193). The likeliness of this
occurring by chance is 1:64,000,000 (Yu et al.,1989).
The involvement of class II molecules in autoimmune disease is much better
understood. The HLA-DQ locus was first thought to be associated with type I diabetes
(IDDM) after studies by Todd and co-workers (1987) using Restriction Fragment
Length Polymorphism (RFLP). Strong confirmation of the proposed association came
from ethnic studies. Two haplotypes were identified to be associated with disease
susceptibility in Afro-Caribbean populations which are neutral in Caucasian
populations. These haplotypes were DR7 and DR9. In Africans, both of these
haplotypes have new RFLP patterns around HLA-DQ (Fletcher et al.,1988a).
Sequencing studies established that the DR7 haplotype, associated with susceptibility
in Africans differs from that in Caucasians at the DQa locus only. The DQa locus on
this haplotype in Africans is identical to that on the DQ haplotype in Caucasians, a
strong susceptibility haplotype. The DR7 haplotype in Caucasians is neutral for
diabetes susceptibility, an unexpected finding as it shares its DQP locus with the DR3
haplotype. The DQa on the Caucasian DR7 haplotype must be responsible for the
neutral effect of this haplotype, and when it is replaced with a susceptibility-associated
DQa in the African population, the DR7 haplotype becomes a susceptibility haplotype
(Todd et al.,1989). Other work on ethnic groups has confirmed the association of DQ
with IDDM (Fletcher et al.,1988b). Todd and co-workers (1987) reported that an
aspartic acid at position 57 of the DQ(3 correlates with resistance to IDDM. However,
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studies by Tait and co-workers (1988) and Sheehy and co-workers (1989) suggested
that in some cases extended haplotype associations cannot be accounted for by DQ
alone, implying that there is an additional DR effect or that another gene is involved.
Specific candidate genes have been identified which account for the association
between HLA and susceptibility to Rheumatoid Arthritis (RA), namely the Dw4 and
Dwl4 genes of the DRfSl locus (Nepom et al.,1987). These two genes are subtypes
of HLA-DR4. Nepom and co-workers (1989) reported that not all patients with RA
carry a Dw4 or Dwl4 gene. However, the majority of DR4 non-carriers expressed an
identical Dwl4-like nucleotide sequence in a portion of the DRp gene. A single
oligonucleotide probe based on this sequence identified not only DR4 susceptibility
genes, but also DR(3 genes in most DR4-negative patients with RA. The nucleotide
sequence recognised by this probe encodes part of the DR(3 polypeptide's first domain,
centred on codon 71, a residue directly implicated in T cell recognition of this allele
(Seyfeird et al., 1988). These findings indicate that a shared nucleotide sequence
contributes shared epitopes among different HLA genes, which would explain the
apparent genetic heterogeneity of RA patients. Therefore, in RA, this fragment of
nucleotide sequence within the DR(3l gene, rather than any single allele, appears to
be the primary susceptibility determinant of the disease.
The class II association with Multiple Sclerosis (MS) is with HLA-DR2 in
Caucasian individuals, although other ethnic studies have indicated that there are
increased frequencies of DR4 and DRw6. Comparison of the sequences of these three
molecules has revealed a sequence in DQP that may be associated with MS (Vartdal
et al.,1989). Studies by Heard and co-workers (1989) have suggested that a haplotype
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other than DR2 may contribute to MS susceptibility.
Whether it is a class I or class II association, susceptibility to autoimmune
disease appears to be multifactorial, with environmental factors also playing a major
role. In other words autoimmune responses could be initially triggered by an
antigenically similar, cross-reacting environmental pathogen. This phenomenon is often
referred to as molecular mimicry. Susceptibility to autoimmune disease is also
polygenic. Because of the multifactoriality and the polygeneity, autoimmune
susceptibility is not inherited in a simple Mendelian fashion (Sinha et al., 1990;
Benjamin and Parham, 1990).
1.6.2. BoLA and Disease:
One of the main reasons for undertaking studies of the BoLA system is that
it may provide a means for selecting more productive or disease resistant cattle, by
identifying BoLA types which are associated with good characteristics, or selecting
against those associated with bad traits.
It has been shown that different breeds of cattle exhibit different frequencies
of BoLA serologic specificities (Oliver et al.,1981; Spooner et ah,1987; Kemp et
al.,1988 and Stear et al.,1988a). Differences between breeds might indicate which
specificities should be studied further to identify possible associations with disease,
growth rate and reproductive performance. The following is a description of what is
known about the BoLA molecules, both class I and class II, and their association with
disease.
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The tick-borne protozoan parasite Theileria parva causes an acute, usually fatal,
disease of cattle known as East Coast Fever. This results in major economic losses
throughout east and Central Africa. It was shown by Goddeeris et jd. (1986) that CD8+
T cells which are important in mediating immunity to T\ parva are restricted by class
I MHC molecules (serologic specificity KN104), and are parasite strain specific. A
more recent study by Goddeeris et al. (1990) further implicates the serological
specificities w7 and w6, the latter appeared to be more dominant in the presentation
of the parasite to the T-cells in animals showing both class I specificities. wl8 was
also seen to have a restricting effect. Bovine class I molecules have also been
implicated in the restriction of CD8+ T cells responses to bovine herpes virus-1.
However, no clear cut associations with particular serotypes were found (Splitter et
al.,1988). It was also recently reported that class I molecule compatibility between the
calf and dam is involved in the aetiology of bovine retained placenta (Joosten et
al.,1991). Perhaps the most striking association between BoLA class I and disease to
date, is the report that the BoLA w8 serotype is significantly associated (p<0.001)
with chronic posterior spinal paresis (PSP), a form of osteophytosis/ankylosing
spondylitis in Holstein bulls. The same serotype showed statistically significant
association with PSP (p<0.0015) in a population of unrelated bulls, it also showed
significant associations (p<0.0008) with PSP in a family of 13 animals sired by a bull
with the serological type w8/w20. All the individuals inheriting the w8 haplotype had
PSP, whilst all the healthy siblings inherited the w20 haplotype (Park et al., 1993).
It was suggested by Glass et al. (1990a,b) that there are definable bovine class
II haplotypes which are functional in antigen presentation and possibly also for Ir
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(immune response) gene effects. In a recent study, it was found that foot and mouth
virus (FMDV) peptides could be restricted by particular MHC class II molecules.
Animals with class II types EDF 5 and 11 confer low responsiveness to the putative
peptide vaccine FMDV15. EDF types 2,3,4,6 and 7, on the other hand, were able to
present this peptide (Glass et al.,1991).
Various other associations between BoLA (mainly class I molecules) and a
number of diseases have been reported. However, most of these studies relied on
statistical analysis and not on any immunological or biochemical data. A description
of these is given below.
The effect of the BoLA system on susceptibility to mastitis was studied in
Norwegian cattle, and it was found that the BoLA type w2 was associated with
resistance, while wl6 was associated with susceptibility (Solbu et al.,1982; Spooner
et al.,1988). Larsen and co-workers in 1985 also indicated that W16 could have an
effect, through an indirect association with the M blood group. w2 in Icelandic cattle,
on the other hand, is associated with susceptibility to mastitis, however, this specificity
is thought to be different from the one reported above (Oddgeirsson et al.,1988).
In a study on a herd of Holstein Friesians it was shown that genes closely
linked, probably within the BoLA complex, are associated with the subclinical
progression of the bovine leukaemia virus (BLV). There is a significant negative
association between the wl4 specificity and the presence of antibodies to BLV-gp51.
The same study showed that susceptibility to the polyclonal expansion of BLV
infected B-cells in BLV infected hosts was associated with either wl or wl2
specificities (Lewinet al.,1988). In addition, Lewin and Bernoco (1986) demonstrated
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that in a herd of Shorthorn cattle, resistance to B-cell proliferation in BLV-infected
cows segregated with w4 and w7-bearing haplotypes, and susceptibility with w26
bearing haplotypes. Studies by Stear etal. (1988b) and Hines et al. (1985) associated
w6 with susceptibility to Persistant Lymphocytosis (PL) (another form of infection
with BLV). Evidence was given by Hines and co-workers (1985) that susceptibility
to (PL) and lymphosarcoma is associated with wl5 in Holsteins and w31 in Jerseys.
These results excluded the possibility of a direct effect of BoLA specificities, but
suggested the existence of a linked effect. Recently, the class II BoLA allele, or a very
closely linked gene, was shown to be associated with resistance to PL (van Eijk et
al.,1992). Other associations with tick infestation, cancer eye, worms and even weight
gain and milk production were reported (see Stear et al., 1984, 1988c, Stear, 1988 and
Hines et al., 1986).
1.7. THE STUDY OF THE MHC AND VACCINE DESIGN:
A better understanding of the structure and function of the MHC molecules is
immensely important to the design of safer, more potent and successful vaccines the
ultimate aim in the application of such knowledge. An ideal vaccine would produce
complete protection from infection after a single injection, evoke minimal side effects,
be readily available, cheap, stable and easy to administer.
Traditional vaccines consist of either live attenuated or killed organisms. Such
vaccines have considerable inherent problems some of which are: high restriction to
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strain and type specificity due to continuous antigenic variations in viruses and
parasites; difficulties in production, storage and delivery; contaminating materials and
undesirable side effects. Also, there are still many viral and parasitic diseases for
which no effective vaccine exists. Therefore, alternative approaches to vaccine
preparation are being sought.
The use of synthetic peptides for vaccination is one alternative which is being
explored extensively. It is attractive due to the simplicity of the approach, the
information it brings to the molecular understanding of the immune response
requirement for protection and the enormous practical advantage that such products
could offer. These vaccines usually constitute small peptides carrying epitopes of the
organism against which the vaccine is designed. By selecting these epitopes only, it
should be possible to exclude others which may elicit deleterious immune responses.
Additionally, peptide vaccines are chemically defined, therefore, free of infectious
material, and can be readily and cheaply synthesized in unlimited quantities (Arnon
and Horwitz,1992). To synthesize a peptide which can elicit an immune response
against foreign protein, it is necessary to determine the sequence of amino acids which
comprises the necessary immunogenic determinants. The nature of such peptides and
the way they are presented to the immune system has recently become clearer.
Processed antigenic peptides bind to the class I and II molecules of the immune
system only if they have the correct code or motif for the MHC molecules present
(Sette et ah,1988; Falk et al.,1991; Madden et ah,1991; Jardetsky et ah,1991; van
Bleek and Nathenson,1991; Hunt et ah, 1992; Hunt et ah, 1992a,b).
These findings have enabled different groups to predict the sequences of peptides that
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would bind better than others to the same MHC class I molecule (Falk et al.,1991;
Tsomides et al.,1991). Similar predictions in the context of murine class II molecules
(I-Ad and I-Ed) were made by Sette and co-workers (1989).
This type of work is invaluable in its potential application to peptide vaccine
design. However, in order to be able to direct a certain peptide to elicit a humoral or
a cell-mediated immune response and protective immunity it is vital to find the
delivery system which would introduce these peptides into the correct presentation
pathway. Such delivery systems, whether chemical or biological, are currently being
designed and a review of some is given below.
Immunisation with free peptide could in some cases lead to protective
immunity. Kast and co-workers (1991) and Schulz and co-workers (1991), working
on, nucleoprotein T cell epitopes from Sendai virus and Lymphocytic
Choriomeningitis Virus (LCMV) respectively, reported that immunisations with
peptides from these proteins elicited CD8+ T cell responses in mice.
Schild and co-workers (1991) reported that coupling various peptides of the
influenza virus to the lipopeptide tripalmitoyl-S-glycerylcysteinyl-seryl-serine (P3CSS)
was successful in inducing virus-specific CD8+ T lymphocytes. This response was
comparable with the priming efficiency seen with the infectious virus itself and was
better than the response induced by the peptide alone. Deres and co-workers (1989)
reported that the peptide corresponding to the sequence comprising amino acids 147-
158 of the influenza nucleoprotein, when covalently linked to P3CSS, induced high
affinity CD8+ T cells as does the infectious virus.
Another method for the development of completely synthetic products
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containing both antigen and carrier is the multiple antigen peptide (MAP) system. The
surface of this macromolecule consists of multiple clusters of the antigen epitope with
a small oligolysine core at the centre. This system has the advantage of being
completely chemically defined, containing either multiple copies of a single epitope
or different antigenic peptides attached to the same macromolecule (Tarn,1988).
Synthetic peptides from the V3 region of the gpl20 protein of IIIB, RF and
MN HTV-1 isolates were used as the antigen. MAP consisting of various chain lengths,
from 11-24 residues, were prepared in a monoepitopic configuration containing four
repeats of each individual peptide. They were synthesized in parallel in a diepitope
configuration adding at the carboxyl-terminus of the V3 peptides a conserved
sequence, known to be a CD4+ T cell epitope of gpl20. The antibody response elicited
by the monoepitope constructs were measured in three experimental species and was
found to be species dependent. Diepitope MAPs were immunogenic in all three
species and elicited significantly higher antibody titers than those raised by
immunisation with the monoepitope MAPs. These results demonstrated the potential
usefulness of a MAP system for the production of an HIV vaccine (Nardelli et
al.,1992).
The Foot and Mouth disease virus (FMDV) was one of the earliest viruses in
which a synthetic peptide approach was attempted. The MAP approach was employed
using the virus-neutralising antibody inducing peptide 141-160 of the VP1 protein.
Monomer, tetramer and octamer structures of this peptide were examined. The
tetrameric structure was found to give the optimal response, with levels of neutralising
antibody comparable with those obtained when whole FMDV was attached to various
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carrier proteins (Francis et al.,1991).
The efficiency of the MAP system was demonstrated using parasites. The
circumsporozoite protein (a major malaria sporozoite surface antigen) of Plasmodium
falciparum, which consists of the four amino acids NANP repeated up to 40 times was
used. It has been shown that synthetic and recombinant NANP peptides were
immunogenic only in H-2b mice (Good et al., 1986; del Giudice et al.,1986; Tonga et
al.,1986; Lussow et al.,1990). The incorporation of this repeated sequence of the
NANP peptide in a MAP system seem to overcome this restriction. This function did
not appear to be due to the peculiar assembly of the NANP sequence. In fact, MAPs
with repetitive sequences from the same protein taken from other strains of the
parasite did not overcome the genetic restriction of the immune response to the linear
peptides. This data suggested that the immunogenicity of the P. falciparum NANP
repeats can be dramatically changed and increased when the MAP system is used.
Perhaps the best example of a potential recombinant vaccine vehicle is the live
attenuated bovine tubercle bacillus BCG (Bacille Calmette-Guerin). This multivaccine
vehicle has been the most widely used in vaccines since 1948, with approximately half
the worlds population being exposed to it at one time, it can be given at birth, has the
ability to sensitize to tuberculoproteins 5-50 years after a single inoculation, it is a
potent adjuvant in a variety of species, could be orally administered, heat stable and
is inexpensive to produce. Additionally, recombinant BCG was shown to express a
number of viral, bacterial and parasitic antigens (Stover et al.,1991).
Hybrid genes containing DNA fragments of HIV-1 Gag, Pol and Env
precursors fused to the microbacterial promoter and translation start site hsp70 so that
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they completely replace the hsp70 coding sequences, were inserted into pYUB12 (a
BCG autonomous replicating plasmid vector). The recombinant vector was introduced
into the Pasteur strain M.bovis BCG by electroporation. BALB/c mice intravenously
inoculated with this recombinant vector had low but detectable antibody responses
demonstrating that the recombinant BCG can elicit humoral responses to foreign
proteins produced by bacillus. In addition, mice inoculated with the BCG-HIV Gag
recombinant produced cell-mediated immune responses as measured by cytokine
production and the cytotoxic activity of spleen cells from these animals (Aldovini and
Young, 1991).
The above findings when combined with the various features of BCG and the
ease with which bacteria can be manipulated makes it possible to tailor a BCG
vaccine that would maximise immune responsiveness.
Other bacterial delivery systems, such as attenuated Salmonella typhimurium,
have been used to introduce a plasmid encoding the influenza nucleoprotein gene from
A/NT/60/68 virus. The results showed that the bacterial vector expressing the viral
gene induces both humoral and cell-mediated immune responses. However, only CD4+
virus specific T cells capable of proliferation were readily induced, and in some cases,
class II MHC restricted cytotoxicity was detected (Tite et al.,1990). Similar systems
have been studied with a variety of recombinant vaccines (Leclerc et al.,1990; Schodel
et al.,1990; Newton eta].., 1989).
The refinement of these vector systems, together with the accumulating
knowledge concerning the way in which peptides are presented to the cells of the
immune system by the MHC molecules, can only push us ever closer to finding a
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reliable and safe system of peptide vaccines.
It is clear from the above that the study of the MHC molecules in humans as
well as in other important species is of great benefit. The better understanding of the
functional aspects of these polymorphic products can only come from detailed studies
of their basic structure and assembly. As cattle are important economically all over
the world, the understanding of the basics of their immune system is a priority so that
this knowledge can be used in producing healthier, more productive animals. The
following pages will carry a description and analysis of experiments carried out with





Cattle have been part of agricultural everyday life for thousands of years. The
first evidence for the domestication of cattle comes from tomb pictures and statues
depicting cattle being milked and butchers at work. These findings led archaeologists
to conclude that cattle were domesticated between 6000 and 5000 B.C. in
Mesopotamia (Friend, 1978). Ever since domestication, cattle have spread with the
migration of people, and have undergone a great deal of selection and faced a wide
variety of pathogens. Of high interest in animal genetics and breeding are the
possibilities of enhancing resistance to various disease pathogens. In order to be able
to select for healthier animals it is important to have genetic markers, these can have
either a direct or indirect effect. The central role of the MHC to the health of the
animal and its indirect effects on growth and development makes it of particular
interest as a genetic marker for selection studies. In order to fully appreciate the power
and influence of the MHC, it is essential to understand its genetic and molecular
structure as well as the influence of each of its products.
Most of the knowledge about the MHC of cattle (BoLA), over the first decade
of its study has come from serological studies. Over the past five years much has been
done to employ more sensitive methods in the study of the BoLA system, although
they represent only the first few steps along a very long path towards an
understanding of the true complexity of the bovine MHC.
Therefore, this project was designed to use biochemical methods to shed some
light on the polymorphism and origins of the molecules expressed by the BoLA class
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I encoding region. The serological studies, which represent the vast majority of
investigative studies on the BoLA system, have indicated the presence of a single
highly polymorphic locus encoding class I molecules. However, other biochemical and
molecular biological studies have indicated that the system is much more complex
than is observed by serology alone. One biochemical method employed recently to
study the BoLA system is 1D-EEF. Results from studies using this technique give
highly complex patterns from individual animals, these results contrasted sharply with
those obtained from serology. Therefore, experiments were designed to investigate the
origin of this complexity and to determine whether it is the product of the post-
translational modification of a small number of polypeptides, two in the case of a
single heterozygous locus or, on the other hand, products of several distinct class I
loci.
The initial hypothesis was that the complexity observed with 1D-IEF is the
product of differential post-translational modifications of the products of one or two
class I loci. Post-translational modifications that could be responsible for the charge
heterogeneity observed include glycosylation and phosphorylation. Alternative splicing
of pre-mRNA is a post-transcriptional modification which is usually reflected in the
protein product. This mechanism could give rise to isoforms of the same molecule.
The effects of glycosylation were addressed using the enzymes neuraminidase
and endoglycosidase F/N-glycosidase F, to treat 35S methionine labelled class I
molecules that were immunoprecipitated using monoclonal antibodies. All samples
were analysed on SDS-PAGE and 1D-IEF gels.
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The effects of phosphorylation were investigated by labelling cells with 32Pj and
then immunoprecipitating the class I molecules and analysing the samples by SDS-
PAGE and 1D-IEF. These samples were compared to others from cells labelled with
35S methionine. Additionally, immunoprecipitated samples from cells labelled with 35S
methionine were subjected to enzymatic digestion with potato acid phosphatase and
analysed by SDS-PAGE and 1D-IEF.
The possibility of alternative splicing of pre-mRNA having an effect was dealt
with indirectly using two-dimensional electrophoretic analysis. Furthermore, to test
whether the molecules observed did in fact have structural differences that might be
due to differences in their primary structures, partial digests of these molecules were
analysed by peptide mapping employing the enzyme endoproteinase Glu-C (V8).
To further understand the origin and expression pattern of the molecules
observed, the AAS used in serology were used in the immunoprecipitation of their
targets and these samples were compared to those produced by using monoclonal
antibodies.
Finally, the available BoLA class I sequences in addition to the HLA-A2
sequence were subjected to structural analysis using the GCG computer software
package and the results were compared to what is known about the structure of the
class I molecules of the HLA system.
The details of the methods used and the results from the experiments outlined
are given in chapters 3 and 4. A discussion of these results and a conclusion are given
in chapter 5. The details of the materials, and other information regarding the





3.1. LYMPHOCYTE PREPARATION AND METABOLIC LABELLING:
The recipies of all buffers and media and information about molecular mass
markers and suppliers are given in appendix Al.
3.1.1 Lymphocyte preparation:
Lymphocytes were prepared by standard ficoll/hypaque centrifugation. 20ml
heparinised blood (25U/ml) was diluted with an equal volume of HBSS, layered onto
12.5ml ficoll/hypaque (s.g. 1.069) and centrifuged at 1500xg (IEC Centra-8) for 25
mins. at 37°C. The lymphocytes were harvested from the ficoll/plasma interface and
washed 3 times with HBSS. The cells are resuspended in 3ml of tissue culture
medium (MEM (Gibco)+ 10% foetal calf serum), counted and numbers adjusted to
4.5xl07/ml. This is sufficient for 3 immunoprecipitations (1.5xl07 each).
3.1.2 Metabolic radiolabelling:
4.5xl07 cells were centrifuged at 250xg for 10 mins., resuspended in 2.5ml of
methionine free medium and incubated at 37°C in an atmosphere of 5% COz for 30
mins.. 35S methionine (15mCi/ml, Amersham) was added to a concentration of
20uCi/ml and the cells were incubated overnight under the same conditions as above.
62
For phosphorylation, cells are incubated in 1ml of phosphate free buffer for 90 mins.,
at 37°C then incubated with 80uCi/ml of 32Pi (lOmCi/ml, Amersham) for 3 hrs at 37°C.
3.2. IMMUNOPRECIPITATION OF BoLA CLASS I MOLECULES:
Labelled cells were centrifuged for 5 mins. at 200xg and washed once by
resuspending in 1ml PBS, the sample is then transferred to an Eppendorf tube and
centrifuged at 10,000xg for 20 sec.. The pellet was then resuspended in 1ml of TX114
lysis buffer and incubated on ice for 30mins.. The cell lysate was centrifuged at
7000xg for 10 mins. at 4°C. The supernatant was transferred to a new tube and
incubated at 37°C for 4 mins.. The detergent/aqueous phases were subsequently
separated by centrifugation at 200xg for 4 mins. at 37°C and the aqueous phase was
discarded. The labelled lysate was precleared by incubating with 4ul of normal rabbit
or mouse serum and incubated on ice for 30mins. with 1ml NET buffer. Pansorbin
cells from Staphylococcus aureus (50ul of 1/10 solution in NET buffer, Calbiochem)
was added and incubated for 15 mins. (on ice). The samples were then centrifuged and
the supernatant is transferred to a fresh tube. The last step was repeated.
330ul of labelled lysate was used for each immunoprecipitation and was
incubated with 4ul of MAb (ascitic fluid) or 50ul of AAS on ice for 75mins.. The
MHC class I/antibody complexes were subsequently precipitated by incubating with
lOOul of Pansorbin cells (for MAb) or lOOul neat Gammabind G (BDH, for AAS) on
ice for 30 mins. Preparations were then centrifuged at 5000xg for 4 mins., and the
supernatant was discarded. The pellet was then washed x4 in 0.5ml NET buffer. After
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final wash, the pellet was resuspended in lOOul of lU/ml neuraminidase in 50mM/l
sodium acetate, pH 5.5 containing 154mM/l NaCl and 9mM/l CaCl2 (Behring) and
incubated at 37°C overnight. A further 0.1U of neuraminidase was added and
incubated as above for an additional 6 hrs.. The supernatent was removed and the
appropriate sample buffer for each application were as follows: The SDS-PAGE
sample buffer contained 2% SDS, 20% glycerol, 0.125M Tris pH 6.8, 0.004%
bromophenolblue and 5% 2-mercaptoethanol, the samples were boiled for 2mins.
before application to the gel. The IEF sample buffer contained 28.5g urea, 1ml
ampholine pH range 3.5-10, 1ml 10% NP40 and 2.5ml 2-mercaptoethanol. The
samples were incubated at 37°C for 30mins. prior to application to gel.
When the enzymes EndoF and Potato acid phosphatase were used, the samples
were incubated with a variety of enzyme concentrations (0.1-0.4U of EndoF and 0.15-
0.25U of potato acid phoaphatase) for various lengths of time (3hrs-overnight)(see
Figs. 4.5, 4.6 and 4.9).
3.3. SDS-POLYACRYLAMIDE GEL ELECTROPHORESIS:
12% polyacrylamide gels were set using solutions described in appendix A.l.
30ul of sample was added to each well and fractionated by electrophoresis at 200v for
40mins for mini gels using the Mini pll system (BioRad). Larger gels (20x20cm) were
run at 70v until samples reach the interface between the stack and resolving gels and
then at 150v for 5hrs. The gels were removed, incubated with DMSO twice for
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30mins. each and then in PPO/DMSO (250g/l) for 3hrs.. After an additional 30min.
incubation in tap water the gels were dried and visualised by autoradiography using
Kodak X-OMAT S x-ray film for 7 days at -70°C.
3.4. 1D-ISOELECTRIC FOCUSSING:
Gel solutions (see appendix A.l) were poured into assembeled apparatus and left
to set. The bottom spacer and comb were then removed and the wells were rinsed with
DH20. The bottom reservoir of the IEF apparatus was filled with 20mM H3P04 and
the gel assembly was then clipped into position on the IEF apparatus. Care was taken
to ensure that the bottom of the gel was in contact with the buffer. Any gaps between
the top of the gel assembly and the top reservoir were sealed with 1% agar and
petroleum gel. Two wells at either end of the gel were also filled with 1% agar. The
samples were incubated with 25-30ul of sample buffer for at least 30 mins. at 37°C.
They were then centrifuged at 10,000xg for 4 mins. and loaded onto the gel. The
samples were overlaid with 8-10ul of overlay buffer and the samples were further
layered with 50mM NaOH as top tank buffer. Gels were run at increasing voltage
from 400v-950v until equilibration (overnight). The gels were then removed and
treated with DMSO and DMSO/PPO as described in section 3.3. The banding patterns
were visualised by autoradiography by incubating at -70°C for 7 days.
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3.5. 2D ISOELECTRIC FOCUSSING/SDS-PAGE ELECTROPHORESIS:
3.5.1 First dimension (Mini IEF):
This method was carried out using the BioRad mini 2D cell. The IEF gel
solution (29.7g Urea, 8.3ml Acrylamide 30T/1.6C, 3ml Ampholines of which 75% was
pH 5-7, 18% pH 3.5-10 and 7% pH7-9, lOOul ammonium persulphate, 50ul TEMED)
was allowed to flow gently down the side of the casting tube filling the IEF tubes
from bottom to top and the preparation was left to set.
The second dimension gels were prepared as in section 3.3. The capillary tubes
were removed from casting tube and rinsed with water. The tubes were connected to
sample reservoirs. Samples were prepared as in section 3.4. and were added to the
reservoir. Top and bottom buffers were added to the apparatus. The gels were run at
500v for 10 mins. followed by 60 mins. at 1500v, the tubes were removed from holder
and attached, to tube gel ejector, partly filled with equilibration buffer.
3.5.2 Second Dimension:
Each IEF tube was layered onto a 12% SDS-PAGE as a second dimension.
Electrophoresis was then carried out as described in section 3.3. No agarose was used
to hold gels down, lul of 14C labelled low molecular mass markers (Sigma) was added
to the gel.
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3.6. PEPTIDE MAPPING ON THE SECOND DIMENSION:
The procedure is as described in section 3.5. with the following modifications:
a. After removing the 2D equilibration buffer. The tube gel was overlayed with lOOul
of V8 protease (Boehringer Mannheim) dilution buffer containing 2ul of enzyme
solution. The buffer was then sealed onto the tube gel with 1 % agarose.
b. The gel was run until the dye front reached the interface between the stack and the
resolving gel, when the procedure was stopped for 20-30 mins. to allow digestion to
take place. The procedure was then continued as in section 3.5..
3.7. SEQUENTIAL IMMUNOPRECIPITATION OF BoLA CLASS I
MOLECULES:
The procedure here was the same as that described in section 3.2., however,
in this case the samples were subjected to three consecutive cycles of
immunoprecipitation with W6/32 (8ul each were added per sample of 2xl06 cells).
That was then followed by one cycle of immunoprecipitation with IL-A88 (lOul).
Pellets collected at each stage were treated as described in section 3.4..
3.8. TISSUE CULTURE:
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T. annulata transformed bovine T cells (Kind gift from Dr.E.Glass) were
cultured in 10ml tissue culture medium (RPMI 1640 (Gibco BRL), 25mM Hepes,
200mM L-glutamine, 10% FCS and 5ml of Penicillin/Streptomycin (Gibco BRL) at
10,000U/ml and 10,000 ug/ml respectively) in 80cm2 flasks (Nunc). The cells were
harvested by incubating with 2ml of 0.02% EDTA for 2mins. at 37°C. The cells are
then washed by resuspending in PBS followed by centrifugation at 200xg.
3.9. FACS ANALYSIS:
Cells (107/ml) transformed with the intracellular parasite T, annulata were
harvested as above and resuspended in FACS medium (RPMI (Gibco), 5% horse
serum and 0.2% sodium azide) and kept on ice. 50ul of cell suspension (5x10s
cells/well) was dispensed per well (of 96 well round bottomed plate) followed by
another 50ul of optimally diluted MAb and shaken once (using orbital shaker), the
preparation was then incubated on ice for 30 mins., shaken once during incubation.
The plate was centrifuged at 120xg for 2 mins. and the supernatant was removed and
the cells were washed by resuspension in lOOul FACS medium and centrifuged at
120xg for 2mins.. The washing steps were repeated three times. The cells were
resuspended in 25ul of fluorescent conjugate (1/100 of FITC-rabbit anti-mouse or
rabbit anti-bovine in FACS medium, Nordic Laboratories) and the plate was incubated
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on ice for 30 mins.. The preparation was then centrifuged and washed three times in
lOOul FACS medium, resuspended in lOOul of FACS medium and analysed using
FACscan (Beckton Dickinson). The results were analysed using Consort 30 and Lysis
1 software.
3.10. DEFATTING MILK;
The milk was diluted 1/5 in DH20 and mixed well. The samples were





4.1. THE BIOCHEMISTRY AND EXPRESSION OF BOVINE MHC CLASS I
MOLECULES:
4.1.1. General characteristics:
Bovine class I molecules have been poorly studied when compared to similar
molecules from other species. In this chapter, a series of experiments will be described
with the objective of answering fundamental questions concerning the biochemistry
of the expressed BoLA class I molecules, and their mode of expression.
In all these experiments the class I molecules were immunoprecipitated from
35S methionine metabolically radiolabelled, non-stimulated, bovine peripheral blood
lymphocytes (PBL) lysed in 0.5% TX114 buffer. This detergent phase separates at
temperatures over 20C, hydrophilic proteins are found in the aqueous phase and
integral membrane proteins with an amphiphilic nature, such as class I MHC
molecules, are recovered in the detergent phase (Bordier,1981). The samples are then
treated with neuraminidase to reduce the charge heterogeneity, and then analysed by
1D-IEF or SDS-PAGE. The immunoprecipitated samples were first analysed for their
molecular mass using 12% SDS-PAGE. Figures 4.1, 4.2 show the results from two
different gels. In figure 4.1 three monoclonal antibodies recognising different epitopes
on the class I molecules were used. MAb W6/32 is a mouse antibody that recognises
a monomorphic conformational epitope on the heavy chain of human class la and
some class lb (HLA-G) molecules, which cross reacts with bovine class I molecules




MOLECULAR MASS OF MOLECULES IMMUNOPRECIPITATED WITH
MAbs W6/32. B1.1G6 and IL-A88.
Figure 4.1a 12% SDS-PAGE analysis of neuraminidase treated molecules,
immunoprecipitated from metabolically radiolabeled lymphocytes from animals with
the serotypes wl4/wl7, wl8/wl8 and an animal of unknown serotype {-!-).
Lanes a, b and c represent samples from an animal with the serotypes wl4/wl7,
immunoprecipitated with MAbs W6/32, B1.1G6 and IL-A88 respectively. Lanes d, e
andf represent samples from an animal with the serotypes, wl8/wl8, with the same
MAbs in the same sequence. Lanes g, k and i represent samples from animal of
unknown serotype immunoprecipitated with the same MAbs in an identical sequence
to the previous two animals. The molecular mass markers are indicated by the arrows
on the right. The arrows to the left of the figure represent spill over from the marker
lane. Figure 4.1b represents SDS-PAGE analysis of immunoprecipitations from three











dependent upon the association of the heavy chain with (32m (Parham et al., 1979;
Jefferies and MacPherson,1987; Shimizu et al.,1988). MAb B1.1G6 is another mouse
antibody, which recognises an epitope on the p2m subunit of human class I molecules
(Libeuf et al.,1981), and was a kind gift from Dr.B.Mallison. MAb IL-A88 is a mouse
antibody that recognises a monomorphic non-conformational epitope on the bovine
class I heavy chain (M.Subash, Personal communication) and was a kind gift from
ILRAD. For negative controls see figures 4.1b and 4.3e. Figure 4.2 shows the results
of molecular mass determination experiments using bovine allo-antisera (AAS) instead
of MAb for the precipitation step. The epitopes recognised by the AAS are unknown.
The SDS-PAGE banding pattern obtained using the different MAbs and AASs,
consisted of a doublet with a 43,000-44,000 band which corresponds to the
neuraminidase treated class I heavy chains and is consistent with those of other
mammals. Additionally, a 39,000-40,000 band was also observed. These smaller
molecules, are associated with (32m given their recognition by W6/32 and B1.1G6.
Their sensitivity to neuraminidase, suggests that they are sialated and have traversed
the trans-golgi network (Goochee and Monica,1990). Furthermore, their presence the
detergent phase implies that they retain their hydrophobic region, indicating that they
are membrane associated. Therefore, they are most likely generated by proteolysis of
larger molecules by natural cellular events. Such events have been reported previously
in both humans and cattle (Krangel,1986; Bensaid et al.,1988). The use of protease
inhibitors largely reduces the presence of these molecules on SDS-PAGE with little
effect on the complexity of 1D-IEF (figure 4.8a,b). Bovine p2m (14000) was not




MOLECULAR MASS OF MOLECULES IMMUNOPRECIPITATED WITH
AAS. ED86, ED97, ED100.
12% SDS-PAGE analysis ofneuraminidase treated molecules immunoprecipitatedfrom
animals with the serological types wl5/wl9 and wl8/wl8 (in collaboration with
Mr.R.Oliver).
Lanes a, b and c represent samples from an animal with serotypes wl5/wl9
immunoprecipitated with AAS ED100 (wl9 specific), ED97 (w6 broad) and MAb
W6/32 as control respectively. Lane e represents the molecular mass markers (values
indicated to the right of the picture). Lanes f g and h represent samples from an
animal with serotypes wl8/w!8 immunoprecipitated with MAb W6/32 as control and











4.1.2. BoLA class I heterogeneity in 1D-IEF:
The 1D-IEF patterns obtained using any of the three MAbs, W6/32, B1.1G6
and IL-A88 were very complex. The results are shown in figure 4.3. It was observed
that the patterns produced by MAbs W6/32 and B1.1G6 are very similar. However,
the bands precipitated by B1.1G6 were generally less intense than those precipitated
with W6/32. MAb IL-A88, on the other hand, showed the ability to precipitate an
additional range of molecules with basic pi points not seen with W6/32 or B1.1G6,
referred to as IL-A88+ molecules (figure 4.3c and d). IL-A88, however, exhibited poor
reproducibility in its ability to precipitate these molecules. The molecules shared in
the patterns produced using the three MAbs are most likely to represent class I heavy
chains that are associated with (32m given that W6/32 requires (32m for its reaction and
B1.1G6 is directed against (32m. To determine the nature of the IL-A88+ molecules,
a sequential immunoprecipitation method was used whereby W6/32 was used in the
first round of immunoprecipitations (three cycles) and IL-A88 in the second. The
resultant samples were analysed by 12% SDS-PAGE and 1D-IEF, the results are
shown in figures 4.4a and 4.4b. It appeared that the molecular mass of the molecules,
which constitute the difference between the two patterns (IL-A88+), is approximately
39,000, 4,000-5,000 less than those recognised by W6/32. These molecules are
possibly surface expressed molecules that have dissociated from (32m at the cell
surface due to the absence of, or ill association with, antigenic peptide (Rock et
al.,1991), which would explain the inability of either W6/32 or B1.1G6 to recognise
them. Such molecules are more sensitive to proteolytic digestion than p2m associated




1D-IEF PATTERNS FROM IMMUNOPRECIPITATIONS WITH MAbs
W6/32, B1.1G6 AND IL-A88.
Figures 4.3a and b show a comparison between the 1D-IEF patterns obtained with
MAbs W6I32 and B1.1G6. The animals used had the serological types wl8/Ed99
(4.3a) and -/- (4.3b).
Figures 4.3c and d show a comparison between the 1D-IEF patterns obtained with
MAbs W6/32 and IL-A88. The animals in this case had the serological types w!4/wl7
(4.3c) and wl8/wl8 (4.3d).
Figure 4.3e shows a comparison between an immunoprecipitation with MAb W6I32


















SDS-PAGE and 1D-IEF ANALYSIS OF SEQUENTIAL
IMMUNOPRECIPITATES WITH W6/32 AND IL A88.
Figure 4.4a shows results from SDS-PAGE analysis, lane a, represents the
samples after a first round of immunoprecipitations with the MAb W6/32. Lane b,
represents the samples after the second round of immunoprecipitations with the MAb
IL-A88. The molecular mass markers are indicated to the right of the figure.
Figure 4.4b represents the 1D-IEF patterns of the samples described in figure 4.4a,
lane 1 is the sample immunoprecipitated with W6/32, lane 2 represents the IL A88+
molecules. Lanes 3, 4 and 5 show the products of the, second, third and fourth cycles












lower molecular mass. The class I heavy chains which leave the ER have no absolute
requirement for the association with p2m. Such molecules become fully glycosylated
and reach the cell surface, albeit at low levels (Hansen et al., 1988). Therefore, the IL-
A88+ molecules could arise by either dissociation from p2m at the cell surface or by
totally escaping this association during biosynthesis. Other explanations for the
presence of IL-A88+ molecules cannot be completely discounted. Polymorphism at the
P2m encoding locus could also be responsible for the inability of W6/32 and B1.1G6
to recognise these molecules, by having epitopes which are different to those required
by these MAbs. Such polymorphism in p2m has been reported in mice (Perarnau et
al.,1990). Also, the IL-A88+ molecules could simply lack the appropriate epitope
required for recognition by W6/32. These molecules could also be non-MHC
molecules that co-precipitate with MAb IL-A88.
Class I heavy chains that fail to maintain their association with P2m are
unstable and therefore thought to be functionally inactive (do not take part in antigen
presentation) and are turned over quickly. They do, however, persist at the cell surface
for at least one hour (Ortiz-Navarrete and Hammerling,1991; Rock et al., 1991). Their
transient presence on the cell surface would explain their appearance in the detergent
fraction, it would also explain the poor reproducibility of those basic patterns when
IL-A88 is used. It was also suggested recently that the class I molecules expressed on
the surfaces of p2m-deficient cells have the ability to function as antigen presenting
molecules (Glas et al.,1992).
The confirmation that the molecules detected by this method are actually found
on the cell surface came from the observation that the 1D-IEF patterns obtained with
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W6/32 after metabolic labelling were almost identical to the patterns obtained with
W6/32 after surface labelling with 12SI. The differences were in faintly labelled
molecules (two or three) with more basic pi points that are only seen clearly after
iodination, they appear very faint or not at all after metabolic labelling. This
differential labelling indicates that these molecules either lack or have very few
methionine residues and that their levels of expression are much lower than the more
acidic molecules in the pattern (R.Oliver, personal communication). Additionally,
bovine (32m (basic pi) could only be seen after iodination due to it's lack methionine
residues (Groves and Greenberg,1977). It should be stressed, however, that the
majority of the molecules in the patterns observed are identical regardless of the
labelling method employed. For this reason metabolic labelling was carried out
throughout the experiments described in this section.
4.2.POST-TRANSLATIQNAL MODIFICATIONS AND CLASS I MHC
CHARGE HETEROGENEITY:
Serological studies suggest the existence of a single highly polymorphic locus
encoding BoLA class I molecules. This conclusion was made after the observation that
the BoLA phenotype was usually determined by two allo-antisera with no evidence
of recombination (Anon,1982; Bull et al., 1989; Bernoco et al.,1992). The use of 1D-
IEF, however, reveals the presence of a complex banding pattern of BoLA class I
molecules from each animal. This finding questioned the origin of these molecules.
If the BoLA system had a single encoding locus then this heterogeneity in the IEF
pattern would have to be the product of post-translational modifications. These include
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glycosylation, phosphorylation and alternative splicing of pre-mRNA. This section
reviews the results of experiments to determine whether the complex 1D-IEF pattern
is indeed a result of differences in the post-translational modification of a small
number of allelic products, two in the case of a single functional locus.
4.2.1. Glycosylation:
The oligosaccharide side chains of glycoproteins are assembled while the newly
synthesised proteins are moving through the secretory pathway. Glycoproteins can
carry carbohydrates attached to aspargine (N-linked glycans), and to serine and
threonine (O-linked glycans). N-linked glycosylation starts with the assembly of a
lipid-linked oligosaccharide chain followed by transfer en bloc onto the nascent
protein. The subsequent steps are initiated in the ER and completed in the trans-golgi
network (Brindle,1991).
MHC class I molecules are glycoproteins. HLA class I molecules have been
reported to have a single available site for N-linked glycosylation at aspargine 86
(Parham etal., 1977; Ploegh etal.,1981). Direct chemical analysis of the carbohydrate
moiety of the HLA molecules reveals them to have an approximate molecular mass
of 3,000 (Parham et.al.,1977). Ploegh and co-workers (1981) reported that the
deglycosylated HLA class I molecules analysed using SDS-PAGE exhibited a shift in
molecular mass corresponding to 4,000. The differences in the two reports could be
explained by the poor capacity of the carbohydrate moiety to bind SDS. The
estimation of the molecular mass of glycoproteins using SDS-PAGE always results in
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higher than normal estimates. Generally, however, these errors in estimation
diminished with the decreasing porosity of the gels (Leach et al.,1980). The class I
molecules of the murine H-2 system are also glycosylated at the same position.
However depending on the class I heavy chain expressed, there could be up to two
other oligosaccharide molecules present on mature H-2 molecules at positions 86, 176
and 256 (Kimball et al.,1981). N-linked glycosylation has been reported to have an
effect on the conformation of the class I heavy chain and its subsequent assembly with
p2m (Neefjes and Ploegh,1988). Such conformational changes induced by
glycosylation or the lack of it may alter the ability of MHC molecules to interact with
CD8+ T cells (Black et al.,1981; Boog et al.,1989 and Neefjes et al.,1990b).
To determine the effect of glycosylation on the complexity of the 1D-EEF
patterns observed for bovine class I molecules, samples were treated with
neuraminidase (NA) which removes all sialic acid residues, and endoglycosidase F/N-
glycosidase F (EndoF) which removes all the sugar molecule, en bloc, from the amino
acid backbone. Figures 4.5 and 4.6 show the reproducible results from the treated
samples analysed by 12% SDS-PAGE and 1D-IEF respectively. The 12% percentage
used for SDS-PAGE combines good separation of molecular masses between 20,000-
60,000 while having a suitable level of porosity for the estimation of the molecular
mass of the bovine class I molecules with little associated error. From figure 4.5, the
molecular mass markers are indicated to the right of the picture. Lane a represents the
sample after treatment with neuraminidase which caused a shift in the position of the
molecules on the gel corresponding to a change of approximately 1,000-1,500 in




SDS-PAGE ANALYSIS OF GLYCOSYLATION OF BoLA CLASS I
MOLECULES,
All samples were immunoprecipitated with W6/32. Lane a represents samples treated
with neuraminidase (NA+). Lane b represents the immunoprecipitated sample which
received the same treatment as the other sample but without being treated with any
enzyme (N/T). Lanes c and d are samples treated with 0.1 and 0.3U of EndoF
(EndoF+) respectively. Once again the distance between the heavy and light bands of
the doublet is maintained. However, the whole ofthe doublet loses approximately 4000
from its apparent molecular mass. The molecular mass markers are indicated to the
right of the picture.
EndoF4
NA+ N/T I "l
abed'
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observation indicated that the sugar moiety on bovine class I molecules carries 3-4
residues. Due to the errors involved in the estimation of the molecular masses of
glycoproteins using SDS-PAGE, the terminal sialic acid residues are likely to be 2-3
(as in humans) rather than the estimated 3-4 residues estimated here. Lane b represents
the W6/32 immunoprecipitated sample with no enzymatic treatment. Treatment with
endoglycosidase F/N-glycosidase F causes a shift that corresponded to a 4000 change
in molecular mass (lanes c and d), which corresponds with the presence of a single
N-glycosylated site on BoLA molecules. The doublet pattern described previously was
maintained after both digestions. This indicates that these smaller molecules are in fact
fully glycosylated and have traversed the golgi apparatus and further supports the
suggestion that they are mature molecules that have undergone proteolysis as is
described in section 4.1.2.. The results also indicate that the enzymatic digestion by
NA and EndoF was complete.
Figure 4.6 shows the 1D-IEF patterns of the samples after treatment with NA
and EndoF. Lanes a and f represent the samples after treatment with neuraminidase.
Lanes b, c, d and e represent the samples incubated with a variety of EndoF
concentrations. Treatment of the samples with neuraminidase led to a shift in the
position of all the molecules present to a more basic position and to a reduction in the
heterogeneity of the pattern (Fig. 4.4b). The samples treated with EndoF showed 1D-
IEF patterns similar to those achieved by neuraminidase treatment alone, regardless
of the larger shift in molecular mass observed with EndoF digestion (Fig. 4.5). These
results indicated that removal of sialic acid whether direct (NA) or indirect (EndoF)




ANALYSIS OF THE GLYCOSYLATIQN OF BoLA CLASS I MOLECULES
BY 1D-IEF.
All samples were immunoprecipitated with W6/32. Lanes a andf represents samples
treated with neuraminidase (NA+) in the normal way. Samples b, c, d and e were
treated with 0.1U, 0.2U, 0.3U and 0.4U of EndoF (EndoF+) respectively.
Q
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These results indicate that the complexity of the 1D-IEF pattern from the
neuraminidase treated immunoprecipitations of class I molecules from the PBL of
different animals could not be explained simply as differences in the extent of
glycosylation of a small number of allelic products. The results also indicate that there
is a single N-linked glycosylated site on bovine class I molecules and that the
carbohydrate moiety is complex and could have up to four sialic acid residues. This
is in agreement with results obtained from work with HLA molecules (Parham et
al.,1977; Ploegh et al.,1981). The possible effect of proteolytic digestion resulting from
impurities in the enzymes (NA and EndoF) was not addressed and although unlikely,
their presence could be a source of error (see discussion).
The amino acid sequences available for BoLA class I molecules are also in
agreement with the fact that only a single N-linked glycosylation site is available at
position 86, as described in section 4.5 (Ennis et al.,1988; Brown et al., 1989 Bensaid
et al.,1991).
4.2.2. Phosphorylation:
The phosphorylation of proteins involves the addition of a negatively charged
phosphate group to serine and possibly tyrosine residues. It is thought that
phosphorylation functions as one of the signals required for the intemalisation of the
protein (Capps ct al.,1989).
HLA molecules have a single serine phosphorylation site located in the
cytoplasmic tail of the molecules (Pober et al.,1978). Loube and co-workers (1983)
reported that only a minor proportion of the total cellular class I molecules is actually
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phosphorylated. This was augmented by a report by Eichholtz and co-workers (1992)
where it was suggested that less than 1% of the class I molecules are phosphorylated
at resting levels. The investigation of the available bovine class I sequences suggests
that they also have a potential phosphorylation site in the cytoplasmic tail (Parham et
ah,1988; Brown et ah,1989 and Bensaid et ah,1991).
The phosphorylation of a given amino acid backbone would give the protein
a negative charge, hence, affecting its mobility in 1D-IEF. Therefore, the same class
I allelic product could exhibit two different mobilities, or indeed more depending on
the number of phosphorylated residues present. This differential phosphorylation of
the same molecule could be responsible for the heterogeneity in the IEF patterns
obtained from bovine cells. To investigate this possibility PBM were harvested in the
usual manner. Samples containing 107 cells were incubated in methionine free or
phosphate free culture medium (150mM NaCl, 5mM MgCl2, 5mM KC1, 1.8mM
Glucose, 2mM Glutamine and lOmM Tris-acetate pH 7.4; Pober et al.,1978) for 30
mins. and 90 mins. respectively. Subsequently, they were either labelled with 35S
methionine overnight at a concentration of 25uCi/ml or with carrier free 32Pj at
80uCi/ml for three hours. The cells were then lysed in TX114 buffer containing
phosphatase and protease inhibitors (0.5ml TX114, 0.5ml 1M MgCl2, 10ml 0.5M Tris-
C1 pH 7.4, 0.4mM EDTA, lOmM NaF, lOmM sodium phosphate, 0.4mM sodium
vanadate, ImM PMSF and lOmM Iodoacetamide). The class I molecules were
immunoprecipitated with the monoclonal W6/32. All the samples were treated with
neuraminidase. Samples were then used in SDS-PAGE and 1D-IEF analysis in the




SDS-PAGE ANALYSIS OF 32P LABELLED TOTAL CELL LYSATE.
Cells were metabolically labelled with 32Pifor 3 hours, lysed in sample buffer, boiled






SDS-PAGE AND 1D-IEF ANALYSIS OF W6/32 IMMUNOPRECIPITATED
CLASS I MOLECULES FROM 32P; LABELLED CELLS.
Figure 4.8a shows W6/32 immunoprecipitated samples were analysed on 12% SDS-
PAGE gels and compared to 35S labelled molecules immunoprecipitated with the same
MAb.
Lane a represents the35S labelled sample. Lane b represents the 32P labelled sample.
The molecular mass markers are indicated to right of the figure. Protease and
Phosphatase inhibitors were included in the lysis buffer.
Figure 4.8b shows the results of 1D-IEF analysis of the samples described in 4.8a.









Figure 4.7 shows the X-ray (2 hours at -70°C) of complete cell lysate from
cells labelled with 32Pj for 3 hours. The sample was run on a 12% SDS-PAGE gel. A
number of phosphorylated protein species could be identified, and unincorporated label
was also detected.
SDS-PAGE analysis of detergent extracted W6/32 immunoprecipitated
molecules from cells labelled with either 35S or 32P; is illustrated in figures 4.8a. Only
35S labelled proteins were detected. These results indicate that the surface bound
bovine class I molecules are not phosphorylated. This finding correlates with the
findings of Loube and co-workers (1983) and is also in agreement with the notion that
phosphorylation is a signal for protein internalisation. Figure 4.8b shows the same
samples after 1D-IEF analysis, once again no phosphorylated molecules were
observed.
In another approach to address the same problem, the electrophoretic mobility
of 35S methionine labelled, neuraminidase treated class I molecules was tested before
and after treatment with the enzyme potato acid phosphatase. The pKg of the
phosphate group in serine phosphate is 5.91 (Dawson et al.,1986). At pH 5.9 half of
the phosphate will be electrophoretically silent, at pH 5.3 80% will be un-ionised.
Because most of the class I MHC molecules that have an intact sialic acid
complement exhibit more acidic isoelectric points (pis) (Loube et al.,1983), it was
thought that treating with neuraminidase first would shift the class I molecules to more
basic positions, therefore giving phosphorylated molecules the chance to express
differences in their mobilities on 1D-IEF gels. The results are given in figures 4.9 and
4.10 for SDS-PAGE and 1D-IEF respectively.
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Figure 4.9 shows the SDS-PAGE analysis of samples immunoprecipitated with
W6/32 without subsequent enzyme treatment, samples treated with neuraminidase only
and samples treated with neuraminidase followed by potato acid phosphatase. Previous
studies involving HLA class I molecules have indicated that the phosphorylated class
I molecules from the HLA and H-2 systems have a molecular mass that is
approximately 1000 more than the non-phosphorylated molecules (Loube et al.,1983;
Capps and Zuniga,1990). Figure 4.9 shows that no such differences in mobility were
observed with detergent solubilised bovine class I molecules which exhibited similar
mobilities whether treated with neuraminidase alone or neuraminidase followed by
potato acid phosphatase, and there was no net difference in migration that could be
attributed to differences in phosphorylation. These findings were augmented by the
1D-IEF analysis of these samples shown in figure 4.10. From this figure it could seen
that the bovine class I molecules had identical 1D-IEF patterns before and after
treatment with potato acid phosphatase. These findings further support the results
described above and indicate that the surface expressed bovine class I molecules are
not phosphorylated and that the heterogeneity in the IEF patterns observed for
different animals could not be attributed to differences in the phosphorylation of a
small number of polypeptides.
The activity of the potato acid phosphatase used in these studies was assessed
by testing its ability to dephosphorylate whole milk proteins from transgenic mice (fig.
4.11). Three lines of mice P.C./40.1, P.C./46 and P.C./66.8 containing an insert for the
ovine protein P-lactoglobulin (BLG) were used. This particular insert constituted nine




ANALYSIS OF THE PHOSPHORYLATION OF BoLA CLASS I
MOLECULES BY SDS-PAGE.
All samples were immunoprecipitated with W6/32 and Neuraminidase treated. Lanes
a, b and c represent samples treated with neuraminidase and with 0.15U (3hrs), 0.25U
(3hrs) and 0.15U (overnight) ofpotato acid phosphatase (PAP+/NA+) respectively for
3hrs. Lane d represents a sample treated with nuraminidase only (NA+). Lane e
represents a sample that received the same treatment as the rest of the samples but
without any enzyme (NIT). The molecular mass markers are indicated to the right of












ANALYSIS OF THE PHOSPHORYLATION OF BoLA CLASS I
MOLECULES BY 1D-IEF.
All samples were immunoprecipitated with W6/32. Lane a represents a samples treated
with neuraminidase (NA+) only. Lane b, represents a sample treated with
neuraminidase and 0.15U (6hrs) ofpotato acidphosphatase (NA+/PAP+). No reduction






of the protein starting at position 85. The milk was defatted and samples from each
line were either treated with potato acid phosphatase or left untreated. In the treated
samples, 0.5U of the enzyme was added and the digestion carried out for 5 hours
(0.25U for 3 hours is sufficient). The results are shown in Figure 4.11. A shift in the
position of a and (5 casein as well as BLG was observed after potato acid phosphatase
treatment. The extent of the shift in the case of BLG was not large enough to bring
the genetically engineered molecules back to a position similar to those migrated to
by normal purified BLG, even after taking into account the added mass of the
insertion. These results indicated that the genetically engineered phosphorylated form
of BLG has a slightly different structure from that of the natural protein, and that an
extended form (maintained by SDS) of the genetically engineered structure will also
be different from the extended form of the natural protein and could be responsible
for the abnormal migration observed for the dephosphorylated protein. The results also
indicate that the enzyme is active and that the phosphorylation of proteins retards their
migration, at least in part, in SDS-PAGE systems.
The work involving the transgenics was carried out as part of a collaborative
effort with Drs.E.Hitchin, M.McClenaghan and Mr.K.Dobbie from the department of




ANALYSIS OF POTATO ACID PHOSPHATASE ACTIVITY BY 15% SDS-
PAGE USING MOUSE WHOLE MILK PROTEIN.
Mouse whole milk protein was used to test the activity of the purchased potato acid
phosphatase. The positions of the molecular weight markers are indicated to the right
of the picture and only the relevant part of the gel is shown. Lanes a and b represent
potato acid phosphatase treated and untreated samples respectively, taken from the
transgenic mouse line P.C.140.1. Lanes c and d represent the treated and untreated
samples, respectively, taken from the trasgenic mouse line P.C.I46. Lanes e and f
represent treated and untreated samples, respectively, takenfrom the transgenic mouse
line P.C.166.8, lane g represents purified normal BLG.
The amount of potato acid phosphatase used with the treated samples was 0.5U
(5hrs), however the. same result could be achieved using only 0.25U of the enzyme (gel
not shown). The arrows to the left indicate the position of the phophorylated forms of
a casein, [3 caseins and BLG.











4.2.3. Alternative splicing of pre-mRNA:
Alternative splicing in most cases is a mechanism that gives rise to protein
isoforms that share extensive regions of identity, and varying only in specific domains,
thus allowing for the fine modulation of protein function (Smith et al.,1989).
This mechanism involves the splicing of pre-mRNA at different sites and leads
to different mRNA products from a single gene. Pre-mRNA observed in the class I
system involves three basic forms of alternative splicing. In all three of these forms
a segment canonically used as an exon is alternatively used as an intron, either
completely (form A) or partially (form B). Additionally, a segment canonically used
as a portion of an intron may be used alternatively as a portion of an exon (form C).
All three types of alternative splices have been observed (Lew et ah,1987; Vogel et
al.,1989 and Grossberger ettd.,1990). Alternative splicing could occur in almost every
exon. The products of alternative splicing at the 5' end of the pre-mRNA, for
example, could increase the repertoire of antigenic peptides presented to the immune
system. This form of alternative splicing has been rarely reported, and even when the
mRNA was found no corresponding protein was found (Transy et al.,1984; Lalanne
et al.,1985). The most abundant form of alternative splicing, occurs at the 3' end of
the pre-mRNA. In all these reports the resultant class I molecules are either longer or
shorter than the wild type protein (Archibald et al., 1986; Lew et al., 1986; McLuskey
et al.,1986; Rogers et al., 1986; Vogel et al., 1986; Grossberger et al.,1990; Ishitani et
al.,1992 and Ellis et al.,1993). It was also observed that the ratio of wild type to
alternative splice form, whether it results in a shorter or longer molecule, was
approximately 10:1. Therefore suggesting, that although alternative splicing is a viable
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way of generating variability, it is rare in nature (Lew et al., 1987; Vogel et al.,1989).
The reasons behind alternative splicing are not fully understood. In the MHC
system, isoforms of a certain class I molecule generated by this mechanism are
unlikely to be the products of splicing errors because of their high rate of occurrence
(5-10%) (Lalanne et al.,1985). Due to the fact that most alternative splice events occur
at the 3' end of the pre-mRNA, it could reflect a certain function for the cytoplasmic
domain of the class I molecules (Ellis et al., 1990). The form of alternative splicing
which is most likely to have such functional importance, is the deletion of exon 7
which encodes the portion of the cytoplasmic domain accommodating the
phosphorylation site (Mcluskey et al.,1986; Ellis et ah,1993). The exact role of the
phosphorylation of class I molecules is unknown, however, it is thought that it could
play a role in receptor signalling. The apparent physical interaction of MHC class I
molecules with insulin receptors and other hormones (Fehlmann et al.,1985; Phillips
et al.,1986; Edidin,1986), may implicate them in the transduction of hormone receptor-
mediated signalling. It has been reported that this mechanism could be responsible for
the generation of soluble forms of the class I molecules. The biological function of
such molecules is yet to be determined (Lalanne et al.,1985; Krangel,1986 and Cianetti
et al.,1989). Additionally, structural variation within the intracellular sequences of
class I molecules may lead to different processing pathways (Zuniga and Hood, 1986).
Alternative splicing could, therefore, be responsible for the generation of the
observed heterogeneity in the BoLA 1D-IEF pattern. From the above, pre-mRNA
alternative splices, if expressed, are most likely to give rise to protein products that
differ in their sizes. Therefore, it was thought that such differences could be picked
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up by two-dimensional (2D) SDS-PAGE analysis.
The results are given in figure 4.12 which shows the two dimensional pattern
obtained from immunoprecipitations from lymphocytes exhibiting the serological type
wl4/wl7. Up to 10 charge variants (vl-vlO), were observed, only six of which (v4,
v6, v7, v8, v9 and vlO) showed doublet formations on the second dimension. The
remainder of the molecules only exhibited the heavier of the two variants (44,000).
These results suggest that if alternative splicing is responsible for the generation of the
observed heterogeneity it must result in molecules that are identical in molecular mass,
such a mode of alternative splicing has never been reported previously. This, in
addition to the fact that the products of alternative splicing are usually expressed at
around 10% of the amount of wild type protein, lead us to conclude that the observed
heterogeneity, in the 1D-IEF patterns could not be generated by alternative splicing,
although its occurrence could not be discounted completely.
The 2D patterns also suggested that a number of charge variants split into two
species with differing sizes, once analysed on the SDS-PAGE second dimension. The
presence of more than one doublet in the second dimension at pi positions identical
to those of the heavier molecules argues against the possibility of the smaller
molecules being totally different proteins that just happened to migrate to the same
isoelectric point. It is more likely that these smaller molecules are actually identical
to the larger variant but had been modified, probably by proteolytic enzymes before
or during lysis. The most likely part of the molecule to be digested is the cytoplasmic




2D SDS-PAGE ANALYSIS OF BoLA CLASS I MOLECULES FROM
LYMPHOCYTES WITH THE w!4/wl7.
The immunoprecipitation form an animal with the serotype wl4lwl7 was carried out
using W6I32 and the sample was treated with neuraminidase. The first dimension is
1D-IEF, the second dimension is 12% SDS-PAGE. Ten charge variants (vl-vlO) are
observed all of which have the same molecular mass (44,000). The molecular mass
markers are indicated to the right of the figure.
0 1D-IEF







the amino acid backbone did not affect the net charge of these molecules indicating
that they have an equal distribution of positively and negatively charged residues over
their whole lengths, and the loss of any part does not affect the net charge of the
molecule.
4.2.4. Heterogeneity in the amino acid backbone:
The experiments so far indicate that the complex banding patterns observed
with 1D-IEF from samples obtained from immunoprecipitations of molecules found
in detergent extracts of cell lysates, are not due to differential glycosylation events nor
to differential phosphorylation events. Furthermore, results involving 2D analysis of
these immunoprecipitates revealed that the heterogeneity observed could not be solely
attributed to alternative splicing, although this mechanism could not be discounted
completely.
The observed heterogeneity in IEF pattern could, however, be due to the
expression of different allelic products from different class I loci. To investigate this
possibility, peptide mapping was used with a slight modification to the original
method reported by Cleveland and co-workers (1977). Here the partial digestion of
1D-IEF separated bovine class I molecules was carried out on the second dimension
(15% SDS-PAGE). The endoproteinase Glu-C (V8) from Staphylococcus auerus was
used in performing the proteolytic digestion at the interface between the stack and run
gels. The patterns of peptides generated using this method are characteristic of the
protein substrate and the proteolytic enzyme and are highly reproducible.
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Figure 4.13 shows the pattern obtained from lymphocytes with the specificity
wlO/wll with up to eight charge variants (vl-v8). The partial digestion patterns of all
were different from each other. The intensity of labelling of the different molecules
is different, this could depend on the number of methionine residues in each molecule.
It could, on the other hand, depend on the affinity of W6/32 to the different
molecules. From figure 4.13, molecules vl, v3, v5 and v6 all show complete digestion
of the parent molecules, vl and v6 show a single digestion product each. v2, v3, v4
and v5 each exhibited a digestion pattern with up to four peptides. v7 shows up to
eight digestion peptides and v8 exhibits three such peptides.
Figure 4.14 shows the pattern obtained from lymphocytes with the serological
type wl4/wl7. Seven molecules are seen in the pattern having a molecular mass of
approximately 44000. Four of these molecules, vl, v2, v3 and v5, gave a digestion
pattern with V8 protease. No detectable pattern was observed for v4, v6 and v7. vl
gave a pattern with up to four digestion products, v2 gave 2 digestion products, v3 and
v5 both gave 6 observed digestion products respectively.
The observation that some molecules did not give rise to any digestion
products could be given two possible explanations, the first is that these molecules do
not have any digestion sites available for V8 protease. The second is that their
digestion products simply do not contain any methionine residues, making them




PEPTIDE MAP OF BoLA CLASS I MOLECULES FROM LYMPHOCYTES
WITH A wlO/wll SEROLOGICAL TYPE.
All molecules were immunoprecipitated with W6/32 and treated with neuraminidase.
The first dimension is 1D-IEF. The second dimension is 15% SDS-PAGE. Digestion
with V8 protease was performed for 30mins. in the interface between the stack and



















PEPTIDE MAP FROM BoLA CLASS I MOLECULES FROM
LYMPHOCYTES WITH THE SEROLOGICAL TYPE w!4/wl7.
All molecules were immunoprecipitated with W6/32 and treated with neuraminidase.













Figure 4.15 shows the pattern obtained from lymphocytes exhibiting the
serological specificity wl0/wl7. In this case up to five parent molecules were
observed (vl-v5), all of which exhibited a defined digestion pattern, vl had a single
digestion pattern. v2 exhibited a digestion pattern with 4 digestion products, v3 and
v4 gave identical patterns of 6 digestion products each. v5 gave 2 digestion products.
From the results above the following could be concluded: The vl molecules
in both animals wlO/wll and wl0/wl7 (Figs. 4.13 and 4.15, respectively) have
identical digestion patterns and similar pis on the first dimension. Joosten and co¬
workers (1992) reported that a molecule immunoprecipitated with the MAb IL-A31
raised against a polymorphic determinant on a BoLA molecule from the w 10 serotype,
gives a similar digestion pattern and migrates to a similar position on 1D-IEF as the
molecule vl seen in this experiment (Joosten and co-workers use the same 1D-IEF
system as the one used here). The results described here suggest that vl (Figs. 4.13
and 4.15) and the IL-A31 molecule are identical. v2 from animal wlO/wll exhibits
a similar digestion patterns to v2 from animal wl0/wl7. Due to the fact that the wlO
haplotype is shared between those two animals, it is likely that the vl molecules are
identical in both animals. Furthermore, the molecules v3 and v4 from animal wl0/wl7
(fig. 4.15) appear to be identical to molecules v3 and v5 from animal wl4/wl7 (fig.
4.14), and by the same argument above these molecules could be identical. Molecule
v5 from the animal wl0/wl7 does not share its pattern with any of the molecules
observed with the other animals.
We conclude that each BoLA serological specificity defines a number of




PEPTIDE MAP OF BoLA CLASS I MOLECULES FROM LYMPHOCYTES
WITH THE SEROLOGICAL TYPE w!0/wl7.
All molecules were immunoprecipitated with W6/32 and treated with neuraminidase.
The experimental condition were as described in figure 4.13. In this case the digestion
















allocation of the serological BoLA specificities to a single locus, BoLA-A, is false.
It must be noted at this point that MHC molecules from different species have
very similar primary sequences. For example, the bovine sequence BL-6 shows up to
78% homology to HLA-A,B and C, and that BL-7 shows up to 82% homology with
the consensus human sequence. The class I sequences from the same species have a
much higher degree of homology (Ennis et al.,1988). Therefore, even products of
different loci from the same species could have identical digestion patterns. Hence, it
is difficult to allocate different molecules to different alleles and different loci using
this technique. The only possible way of identifying individual allelic products of an
individual locus with any confidence, is to obtain DNA sequence data. The above
results, however, when taken with the combined results described in previous sections
show that the different charge variants seen from the immunoprecipitates of class I
molecules from individual animals did not arise from differential post-translational
modification events. They also show that these variants have considerable differences
in their primary sequences. The number of these variants indicates the expression of
at least three class I loci on the surfaces of bovine PBL.
The use of comparative peptide mapping, using two or more proteases with
contrasting specificities, could be most effective in obtaining a better picture as to the
identity of individual molecules and remove any comformational artifacts that could
obscure the specific sites of a given protease. Proteases such as V8, elastase,
chymotrypsin, papain are only a few of the choices available for such an undertaking.
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4.3. FURTHER EVIDENCE FOR THE EXPRESSION OF MORE THAN ONE
CLASS I LOCUS:
The use of 1D-IEF produced differing multiple band patterns with samples
from different animals. There is general agreement, relying on serological studies only
that the class I molecules detected are the products of a single highly polymorphic
locus "BoLA-A" (Bull et ah,1989 and Bernoco et al.,1991). The assignment of
serological specificities to one locus was based on the observation that the MHC type
of individual animals is usually defined by two AAS with no evidence of
recombination (Anon, 1982). This sharply contradicts the highly complex patterns
obtained from 1D-IEF. It was therefore essential to investigate and dissect these
banding patterns in order to better our understanding of their origins. To do so it was
important to be able to allocate different bands in a 1D-IEF pattern to different
serological specificites. Two approaches were used to this end. The first depended
upon the visual comparison of various 1D-IEF patterns from the immunoprecipitation
of the class I molecules from the PBLs of different animals using MAb W6/32. This
MAb was chosen because it reacts with class I heavy chains only if associated with
p2m. w6/32 was preferred to B1.1G6 because it exhibited a stronger reaction to BoLA
class I molecules. Further, W6/32 was preferred over IL-A88, because the latter
recognises a linear epitope on class I heavy chains, therefore, has the potential of
precipitating immature molecules (not associated with P2m). The results from the
visual comparison of the 1D-IEF patterns of different animals are given in figures
4.16, 4.17 and 4.18. The allocation of the bands to various serological specificities is
given in the schematic representations accompanying each figure. In each case when
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a band is allocated to a certain specificity then it will carry the number of that
specificity in the schematic figure. Where a band could not be allocated to a certain
specificity it will be marked "?" on the schematic figure. The sign (-) denotes an
unknown serological specificity.
Figure 4.16 shows the IEF patterns of 12 different animals (11 British Friesians
and one longhorn) produced using W6/32. The serological specificities represented
were: w6, wlO, wl4, wl5, wl8, wl9, w20 and ED99. Different serological
specificities were allocated a different number of bands depending on the
reproducibility of a certain pattern with a given serotype. From figure 4.16,
specificities wl4, wl5, w20 coincide with the appearance of three acidic IEF bands.
The serological specificities w6, ED99 and w 19 are consistent with a pattern of 4-5
IEF bands. The ED99 bands appear to be the more acidic than those of w6 or wl9,
which have higher pi points. Seven IEF bands appeared to correspond to the
serological specificity wl8. The pi range of these bands varied widely as seen in
figure 4.16. The specificity wlO showed a variation both in the number of bands
observed and their pi point among different animals. The pattern in lane j of figure
4.16 was from the PBL of a Longhorn animal. This animal had no known serological
type (-/-) and showed an IEF pattern that spanned the entire pH range used in our
gels, with the most basic bands being more intense than the more acidic ones. The
opposite of this was seen with the rest of the animals with the more acidic bands
being more intense than those with higher pis. Serological differences between breeds
have been reported previously (Kemp et al., 1988). Manifestations of these differences




DETERMINATION OF THE IEF BANDING PATTERNS FOR
SEROTYPES: w6, wlO, w!4, w!5, w!8, w!9, w20 and ED99 by visual
comparison.
The class I molecules were precipitated using MAb W6/32. The serological types were
as follows: Lanes a and b, w!8/ED99, Lane c, w6/ED99, lane d, w!0/wl5, Lane e,
wl0lw20, Lanef w!4/wl8, Lane g, wl8/-, Lane h, w!0/ED99, Lane i, wl5/wl9, Lane
j, is a Longhorn animal with unknown serotypes, Lane k, wl0/w!9 and Lane I,
wl0/w!5.
The bands corresponding to different specificities are indicated in the schematic
representation. Bands are allocated to various specificities depending on the
reproducibility of a particular banding pattern with a particular serotype. Bands that
could not be allocated to any serological specificity are marked "?". The banding
patterns showed consistent results with most specificities. Only animals with the wlO
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Figure 4.17a and b, shows the 1D-IEF patterns of cells with the serological
specificities wl, w2, w3, wll, wl4 and two unknowns. Figure 4.17a, shows the
pattern for w3 was consistent with that shown in figure 4.18 and included three bands.
The wll heavily labelled bands were also reproduced. However, only one of the two
faint, more basic bands was observed. In addition to w3, lane "c" had an unknown
specificity the IEF bands that might correspond to it are labelled Figure 4.17b,
shows the more acidic bands corresponding to the specificity wl4. It also shows
that the specificities wl and w2 have seven and four IEF bands respectively, all of
which had higher pis than the wl4 bands. Lane "c" in figure 4.17b also showed an
unknown specificity with a single band marked "?".
Figure 4.18, shows samples that have been treated in the same way as the
samples in figure 4.16. Here, the lymphocytes carried the serological specificities w3,
wll, wl3, wl4, w20, ED99 and an unknown (-). In this figure specificities wl4 and
w20 were consistent with findings in figure 4.16. ED99 showed only three of the five
bands allocated to it in figure 4.16, however, the labelling in that lane (d) was very
poor. The specificity wll showed a consistent pattern of two heavily labelled bands
with two fainter bands, with more basic pis only appearing on two occasions (lanes
a, c and e). The serotype wl3 was consistent with the presence of a single IEF band
and w3 was associated with three bands. The molecules in lane "f were precipitated
from lymphocytes with serological type wl4/-. The bands that correspond to this blank




COMPARISON OF IEF PATTERNS OBTAINED FROM LYMPHOCYTES
WITH w2/14, wl/w!4, wl/-, w3/wll, w3/wll and w3/-.
All samples were immunoprecipitated with W6/32. Figure 4.17a the haplotypes
involved were w3/wll (lanes a and b), w3l- (lane c). The bands that could be
allocated to a certain specificity are denoted with the number of that specificity. Those
that could not be allocated to a certain specificity are marked "?".
In Figure 4.17b, all the samples were precipitated with MAb W6/32. The lymphocytes
were from animals with serotypes, w2/wl4 (lane a), wl/wl4 (lane b) and wll- (lane
c).
(4-17a)
ow3/wll w3/wll w3/- w3/wll w3/wll w3/-




COMPARISON OF IEF PATTERNS CORRESPONDING TO THE
SEROLOGICAL SPECIFICITIES w3, wll. w!3, w!4, w20 and ED99.
All samples were precipitated with W6/32. The serological types were wll/w!3 (lane
a), w3/w!3 (lane b), wlllwl4 (lane c), wll/ED99 (lane d), wll/w20 (lane e) and
wl4/- (lane f).
The bands that could be allocated to a certain serological specificity are denoted with
the number of that specificity. Those that could not be allocated were marked
G
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These results indicated that each serological specificity is represented by a
number of different charge variants that are inherited together which implies the
presence of linkage disequilibrium in the BoLA system. This visual method for the
allocation of IEF bands to serological specificities has good reproducibility.
A second approach to identify the different IEF bands uses the AAS in the
immunoprecipitation step, Gamma-bind G agarose was used instead of Pansorbin to
precipitate the AAS/class I complex, due to the formers higher ability to bind bovine
Ig (McGuire, 1988). Different AAS gave banding patterns that varied in complexity.
In fact some sera did not produce any bands at all. FACS analysis of the different sera
suggested that the ones that were able to produce an IEF pattern had a higher
proportion of IgG than IgM. Conversely the AAS which did not produce a pattern had
similar proportions of IgG and IgM, and were invariably the products of a primary
challenge. The results of the FACS analysis are seen in the appendix (A.2).
Figure 4.19 shows immunoprecipitates from an animal with the serological type
wlO/wl 1. Lane a represents the banding pattern produced using the MAb W6/32. Lane
b is AAS 97 (-ve control) lanes c and d represent immunoprecipitations using the AAS
69 and 71 (wlO specific), lanes e, f, g and h represent the AAS 73, 110, 76 and 102
(wll specific). The combination of the banding patterns of the sera of both
specificities did not fully account for the IEF pattern produced with W6/32.
Furthermore, the MAb recognised molecules with higher pi points (labelled "b") were
not recognised by the AAS and vice versa.
Figure 4.20a and b shows the results of immunoprecipitations from animals




THE IEF PATTERN LYMPHOCYTES WITH THE SEROLOGICAL TYPE
W10/W11 IMMUNOPRECIPITATED WITH AAS.
Lane a, is the MAb W6/32. Lane b, is the AAS 97 (w6 broad, -ve control). Lanes c
and d, are the AAS 69 and 71 respectively (wlO specific). Lanes e,f, g, h, i and j are
the AAS 73,110, 76 and 102 respectively (wll specific). The combined patterns of the
two AAS did not account fully for the pattern produced with W6/32. The MAb
recognised molecules not seen by any of the AAS and vice versa. The molecules
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the specificities wl4 and wl5 were not available, however, the bands corresponding
to them could be assigned visually. The AAS 66 and 97 ( both react to the broad
specificity w6, including its subtypes wl7, wl8 and wl9) and 100 (wl9 specific)
recognised a number of molecules with different pis. These, unlike the molecules
precipitated with AAS 69 and 102 (figure 4.19), were all recognised by W6/32.
Furthermore, the MAb recognised molecules with more basic pis, (denoted "b"), none
of which were recognised by any of the AAS.
The results obtained above suggest that a wide range of molecules with
different pi points are recognised by W6/32. The use of AAS that correspond to the
serological type of any one animal did not account for the full compliment of
molecules as seen with W6/32. Furthermore, in many cases there were discrepancies
between the AAS and the MAb in the particular molecules recognised by each. In
other words, W6/32 had the ability to recognise molecules not recognised by the AAS
and vise versa. These findings suggest that class I molecules in cattle as revealed by
1D-IEF, do not behave as the products of a single highly polymorphic locus. From the
above and from the fact that the majority of the animals used in these experiments
were from the same breed and the same herd, the 1D-IEF patterns were identical for
animals with the same serotypes. It could be suggested that there exists considerable
linkage disequilibrium in the BoLA class I region. This suggestion is augmented by
the fact that animals from different breeds show a distinct 1D-IEF patterns (lane j in
figure 4.16). The presence of strong linkage disequilibrium would make it difficult for
the AAS to distinguish among molecules expressed by the more polymorphic loci.




IMMUNOPRECIPITATIQNS FROM ANIMALS WITH THE
SEROLOGICAL TYPES w!4, w!5, w!7, w!8 and w!9 USING AAS.
Figure 4.20a, shows a comparison of IEF patterns from animals with the serological
types wl8/wl8 and wl5/wl9. Lanes a, b, and c, are lymphocytes with the serology
w!8/wl8 precipitated with AAS a) 100 (w!9 specific), as negative control, AAS 66 and
97 (broad w6) are seen in lanes b and c respectively. Lanes e, f, and g are
lymphocytes with the phenotypes wl8/wl8, wl4/wl7 and wl5/wl9 respectively, all
precipitated with W6/32. Lanes h, i, and j are wl5/wl9 lymphocytes precipitated with
AAS 97, 66 and 100 respectively.
Figure 4.20b, shows lymphocytes with the phenotype wl5lwl9 precipitated with W6/32
(lane a), AAS 97 (lane b) and AAS 66 (lane c) both recognising the broad specificity
w6 and its subtypes (wl7, wl8 and wl9). Lanes d and e represent the AAS 92 and 93
(wl7 specific) and lane f represents samples immunoprecipitated with AAS 86 (wl8
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presence of any less polymorphic loci will be masked by this disequilibrium until
animals with different genetic backgrounds are used in reciprocal immunisation
procedures. Linkage disequilibrium between the class I allelic products has been
reported in the human population (Bodmer and Bodmer, 1978).
4.4. STRUCTURAL COMPUTER ANALYSIS OF THE AVAILABLE BoLA
CLASS I SEQUENCES.
In this section the available bovine class I sequences (Ennis et ah,1988; Brown
et ah,1989 and Bensaid et al.,1991) will be subject to structural analysis using the
GCG sequence analysis software. The results from this section will enable us to draw
conclusions on the similarities or differences between the BoLA molecule's structure
and that predicted for the HLA molecule A2.
4.4.1. Determination of the isoelectric points:
The GCG programme used in this case is called "Isoelectric". It calculates the
isoelectric point of a protein from its amino acid sequence assuming no electrostatic
interactions occur that perturb ionisation. "Isoelectric" makes a plot of the total
positive and negative charges and the net charge of a protein as a function of pH. The
isoelectric point is indicated on the plot (GCG Programme Manual).
The five sequences studied were BL3-6, BL3-7 (Ennis et al.,1988), pBoLAl
(Brown et al.,1989), KN104 and wlO (Bensaid et ah, 1991). The results are shown in
figures 4.21, 4.22 and 4.23. The pi points all fell in the expected range for class I
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molecules at pH 5-7, with wlO having the highest pi point at 6.11 (fig. 4.22) which
is consistant with the higher pis shown by the molecules associated with wlO (section
4.3). BL3-6 had the lowest pi point at 5.24 (fig. 4.21). The IEF method used in these
experiments is more than adequate in its resolution to deal with very small differences




THE PREDICTION OF THE ISOELECTRIC POINTS OF THE BoLA
SEQUENCES BL-6 AND BL-7.
The isoelectric points are predicted for the sequences BL-6 (4.21a) and BL-7 (4.21b)
using the GCG programme "isoelectric". The charged groups involved are given to
the right of each figure. The isoelectric points were 5.24 for BL-6 and 5.27for BL-7.
(4.21a)
ISOELECTRIC of: Bovrrf-bdaPep Oc 273 1 to 339 January 21, 1993 13:17
* = Isoelectric point = 524
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IS0ELECTRC of: BovrrtfccbPep Oc 1350 1 to 337 August 27, 1992 10:36
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THE PREDICTED ISOELECTRIC POINT FOR THE BoLA SEQUENCES
wlO and KN104.
The isoelectric points for the sequences wlO (4.22a) and KN104 (4.22b) are given
using the GCG programme "isoelectric". The isoelectric points were 6.11 for wlO and
5.71 for KN104. The charged groups are given to the right of each figure.
(4.22a)
ISOELECTRIC of: BovrrftkenoPsp Oc 2867 1 to 339 Augjst 27, 1992 10:59

















ISCELECTRC oft Bosn-H«naTxt Oc 5648 1 to 338 August 27, 1992 11:08
* = Isoelectric point = 5.71
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THE PREDICTED ISOELECTRIC POINT FOR THE SEQUENCE pBoLAl.
The predicted isoelectric point for the sequence is 5.74 as given by the GCG





























4.4.2. Prediction of the- secondary structure:
The secondary structure of the bovine class I sequences was predicted using
the GCG programme "Peptidestructure". The secondary structure predictions made by
this programme include, alpha, beta, coil, and turn, measures of antigenicity,
flexibility, hydrophobicity and surface probability are also given. Details of this
programme are given in the relevant section of the GCG users manual.
Peptidestructure makes predictions of the following features of an amino acid
sequence:
1. Secondary structure according to the Chou-Fasman (1978) method.
2. Secondary structure according to the Garnier-Osguthorpe-Robson (1978) method.
3. Hydrophobicity according to Kyte-Doolittle (1982) method.
4. Surface probability according to the Emini (1985) method.
5. Flexibility according to the Karplus-Shulz method.
6. Glycosylation sites.
7. Antigenic index according to Jameson-Wolf (1988) method.
The basic rules for the secondary structure according to Chou-Fasman (CF)
predictions are as follows: (A) For (5-sheets there should be at least three p-forming
residues and not more than one breaking residue within a window of five. (B) For a-
helices there should be four or more a-forming residues and not more than one
breaking residue within six residues. For Garnier-Osguthorpe-Robson (GOR) the
predictions of the secondary structure observe the following rules: (A) The minimum
length for P-sheets is four residues as opposed to five with the CF method. (B) The
minimum length for an a-helix forming stretch is six residues with no restrictions.
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N-linked glycosylation sites are predicted for sites where the residues have the
composition NxT or NxS. When x is D, W and P, the site is taken to be a weak
glycosylation site, otherwise it is a strong glycosylation site.
Caution must be taken when using these methods to interpret the structure of
a given protein. As the predictions made by these programmes are only 50-60%
accurate due to the fact that they rely on statisical information derived from a small
number of primary sequences (Argos,1989 and Rost et ah,1993). The
"peptidestructure" files are presented graphically using the GCG programme
"plotstructure" and the results are given in figures 4.24-29.
The secondary structure of the HLA-A2 molecule has been reported and is
used here as reference, the method of prediction used was that described by Kabsch
and Sander (1983) and was found to be in agreement with the refined three-
dimensional structure of the same molecule (Saper et ah,1991). The (3-strands in each
(3 sheet of each domain are referred to as Sn where n could be any number from 1-7.
The a-helices are given the symbol Hn where n could be any number between 1 and
3. The HLA-A2 secondary structure could be summarized as follows (Saper et
ah,1991):
The a, domain: NH2-S1 (residues 3-12)-S2 (residues 21 -28)-S3 (residues 31-37)-S4
(residues 46-47)-Hl (residues 50-53)-H2 (residues 57-84)-COOH.
The a, domain: NH2-S1 (residues 94-103)-S2 (residues 109-118)-S3 (residues 121-
126)-S4 (residues 133-135)-H1 (residues 138-150)-H2a (residues 152-161 )-H2b
(residues 163-174)-H3 (residues 176-179)-COOH.
The a, domain: NH2-S1 (residues 186- 193)-S2 (residues 198-208)-S3 (residues 214-
121
219)-S3s* (residues 222-224)-S4a (residues 228-230)-S4b (residues 234-235)-S5
(residues 241-250)-S6 (residues 257-262)-S7 (was not detected in the 3D structure)-
COOH.
*
S3s is an additional short strand running antiparallel to S3.
The predicted secondary structure for each of the five bovine sequences are
given below. In each case, whenever the prediction made using this programme gives
an identical or close predictions to those described above that part of the predicted
structure be highlighted in bold type.
1. The predicted secondary structure of BL-6 (Ennis et al.,1988):-
(a) The secondary structure using the GOR method:
The a, domain: NH2-S1 (residues 5-13)-S2 (residues 20-29)-S3 (residues 31-
37)-S4 (residues 72-78)-COOH.
The a, domain: NH2-S1 (residues 108-117)-S2 (residues 121-128)-H1
(residues 135-153)-H2 (residues 163-173)-S3 (residues 176-182)-COOH.
The a, domain: NH2-S1 (residues 196-203)-Hl (residues 112-119)-S2
(residues 243-250)-COOH.
The transmembrane domain (TM): NH2-S1 (residues 280-299)-Hl (residues
300-312)-COOH.
The cytoplasmic domain (C): NH2-S1 (residues 316-323)-S2 (residues 330-
339)-COOH.
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(b) The secondary structure using the CF method:
The a, domain: NH2-S1 (residues 5-15)-S2 (residues 20-29)-Hl (residues 44-
58)-S3 (residues 72-85)-COOH.
The a, domain: NH2-S1 (residues 91-98)-S2 (residues 110-119)-H1 (residues
122-128)-S3 (residues 129-134)-H2 (residues 135-155)-S4 (residues 156-62)-H3
(residues 162-171)-H4 (residues 175-183)-COOH.
The a, domain: NH2-H1 (residues 185- 192)-S 1 (residues 195-208)-S2
(residues 210-219)-H2 (residues 220-235)-S3 (residues 237-248)-S4 (residues 253-
262)-H3 (residues 263-268)-S5 (residues 269-274)-COOH.
The TM domain: NH2-S1 (residues 280-308)-COOH.
The C domain: NH2-S1 (residues 316-323)-S2 (residues 330-336)-COOH.
The diagram representing the above is given in figure 4.24. The figure also
shows the existence of a single N-linked glycosylation site at position 86.
Additionally, the sequence of residues 281-307 was shown to be hydrophobic and




THE PREDICTED SECONDARY STRUCTURE OF THE BoLA SEQUENCE
BL-6.



























2. The predicted secondary structure of BL-7 (Ennis et al.,1988):
(a) The secondary structure using the GOR method:
The a, domain: NH2-S1 (residues 5-13)-S2 (residues 20-29)-S3 (residues 31-
37)-S4 (residues 72-78)-COOH.
The a, domain: NH2-S1 (residues 94-102)-S2 (residues 108-113)-H1 (residues
125-145)-H2 (residues 145-158)-H3 (residues 165-175)-S3 (residues 177-182)-COOH.
The a, domain: NH2-COOH.
The TM domain: NH2-S1 (residues 281-195)-H1 (residues 296-307)-COOH.
The C domain: NH2-S1 (residues 314-320)-S2 (residues 328-337)-COOH.
(b) The secondary structure using the CF method:
The a, domain: NH2-S1 (residues 5-13)-S2 (residues 20-29)-S3 (residues 31-
37)-Hl (residues 47-57)-S4 (residues 65-76)-S5 (residues 76-83)-COOH.
The Oto domain: NH2-S1 (residues 94-102)-S2 (residues 108-118)-H1 (residues
125-160)-H2 (residues 165-171)-H3 (residues 179-184)-COOH.
The a, domain: NH2-H1 (residues 185-196)-S 1 (residues 200-210)-H2
(residues 211-239)-S2 (residues 240-250)-S3 (residues 254-264)-H3 (residues 264-
270)-S4 (residues 271-276)-COOH.
The TM domain: NH2-S1 (residues 281-307)-COOH.
The C domain: NH2-S1 (residues 314-320)-S2 (residues 328-335)-COOH.
The transmembrane domain extends from residues 280-303 which are shown to be





THE PREDICTED SECONDARY STRUCTURE OF THE BoLA SEQUENCE
BL-7.
























3. The predicted secondary structure of pBoLAl (Brown et al.,1989):
(a) The secondary structure using the GOR method:
The a, domain: NH2-S1 (residues 5-13)-S2 (residues 20-29)-S3 (residues 31-
37)-Hl (residues 57-66)-S4 (residues 70-76)-S5 (residues 80-85)-COOH.
The a, domain: NH2-S1 (residues 111-117)-S2 (residues 121-129)-H1
(residues 130-147)-H2 (residues 148-157)-H3 (residues 165-173)-S3 (residues 175-
182) COOH.
The a, domain: NH2-S1 (residues 198-203)-S2 (residues 225-235)-COOH.
The TM domain: NH2-S1 (residues 281-297)-Hl (residues 298-312)-COOH.
The C domain: NH2-S1 (residues 317-323)-S2 (residues 331-339)-COOH.
(b) The secondary structure using the CF method:
The a, domain: NH2-S1 (residues 5-15)-S2 (residues 31-37)-Hl (residues 50-
58)-H2 (residues 64-71)-S3 (residues 72-87)-COOH.
The a, domain: NH2-S1 (residues 92-98)-S2 (residues 111-119)-H1 (residues
123-155)-S3 (residues 162-172)-H2 (residues 176-182)-COOH.
The a, domain: NH2-H1 (residues 186- 192)-S 1 (residues 196-209)-S2
(residues 212-218)-H2 (residues 221-232)-H3 (residues 240-250)-S3 (residues 254-
263)-H4 (residues 264-269)-H5 (residues 270-276)-COOH.
The TM domain: NH2-S1 (residues 281-309)-COOH.
The C domain: NH2-S1 (residues 315-323)-S2 (residues 330-339)-COOH.
The hydrophobic region extended from residues 281-307 and there was a single




THE PREDICTED SECONDARY STRUCTURE OF THE BoLA SEQUENCE
pBoLAl.






































4. The predicted secondary structure for a wlO molecule (Bensaid et al.,1991):
(a) The secondary structure using the GOR method:
The a, domain: NH2-S1 (residues 5-13)-S2 (residues 20-29)-S3 (residues 31-
37)-Hl (residues 60-67)-S4 (residues 70-78)-COOH.
The QCo domain: NH2-S1 (residues 111-117)-H1 (residues 124-158)-H2
(residues 165-173)-S2 (residues 177-183)-COOH.
The a, domain: NH2-S1 (residues 186-193)-S2 (residues 197-204)-S3
(residues 226-234)-S4 (residues 259-264)-COOH.
The TM domain: NH2-S1 (resides 280-298)-Hl (residues 299-309)-COOH.
The C domain: NH2-S1 (residues 316-223)-S2 (residues 330-339)-COOH.
(b) The secondary structure using the CF method:
The a, domain: NH2-S1 (residues 5-15)-S2 (residues 31-37)-Hl (residues 44-
58)-H2 (residues 60-72)-S3 (residues 70-78)-COOH.
The a, domain: NH2-S1 (residues 93-103)-S2 (residues 111-117)-H1 (residues
121-158)-S3 (residues 159-165)-H2 (residues 166-174)-H3 (residues 177-183)-COOH.
The ou domain: NH2-H1 (residues 185-191 )-S 1 (residues 197-209)-S2
(residues 212-218)-H2 (residues 220-234)-H3 (residues 239-249)-H4 (residues 253-
268)-S3 (residues 269-274)-COOH.
The TM domain: NH2-S1 (residues 280-309)-COOH.
The C domain: NH2-S1 (residues 316-223)-S2 (residues 330-337)-COOH.
The hydrophobic residues extend over position 281-307 and there is a single




THE PREDICTED STRUCTURE OF THE BoLA SEQUENCE wlO.
The secondary structure of the a sequence which is part of the wlO haplotype as


































5. The predicted secondary structure of KN104 (Bensaid et al.,1991):
(a) The secondary structure using the GOR method:
The a, domain: NH2-S1 (residues 5-13)-S2 (residues 20-29)-S3 (residues 31-
37)-Hl (residues 47-54)-H2 (resides 60-76)-COOH.
The ou domain: NH2-S1 (residues 106-112)-S2 (residues 122-128)-H1
(residues 134-144)-H2 (residues 164-173)-COOH.
The a, domain: NH2-S1 (residues 177-183)-H1 (residues 194-203)-H2 (resides
210-219)-S2 (residues 240-250)-COOH.
The TM domain: NH2-S1 (residues 280-299)-Hl (residues 300-309)-COOH.
The C domain: NH2-S1 (residues 315-323)-S2 (residues 330-338)-COOH.
(b) The secondary structure using the CF method:
The a, domain: NH2-S1 (residues 5-13)-S2 (residues 20-29)-S3 (residues 31-
37)-Hl (residues 43-55)-H2 (residues 59-70)-S4 (residues 71 -76)-S5 (residues 78-85)-
COOH.
The CKo domain: NH2-H1 (residues 90-97)-Sl (residues 121-129)-H2 (residues
133-150)-S2 (residues 155-161)-H3 (residues 163-169)-COOH.
The ou domain: NH2-H1 (residues 176-184)-H2 (residues 185- 196)-S 1
(residues 197-208)-S2 (residues 211-219)-H3 (residues 221-234)-S3 (residues 240-
259)-S4 (residues 254-264)-H4 (residues 265-268)-S5 (residues 269-274)-COOH.
The TM domain: NH2-S1 (residues 280-308)-COOH.
The C domain: NH2-S1 (residues 314-320)-S2 (residues 330-338)-COOH.
The hydrophobic region extended between residues 281-305 and there was a




THE PREDICTED SECONDARY STRUCTURE OF THE BoLA SEQUENCE
KN104.







































6. The predicted secondary structure of HLA-A2 (Koller and Orr,1985):
(a) The secondary structure using the GOR method:
The a, domain: NH2-S1 (residues 5-12)-S2 (residues 20-29)-S3 (residues 31-
37)-Hl (residues 60-71)-S4 (residues 72-82)-COOH.
The Op domain: NH2-S1 (residues 95-100)-Hl (residues 122-160)-H2
(residues 163-173)-COOH.
The ou domain: NH2-H1 (residues 185-205)-Sl (residues 228-234)-S2
(residues 243-250)-COOH.
The TM domain: NH2-S1 (residues 280-299)-Hl (residues 300-309)-COOH.
The C domain: NH2-S1 (residues 318-324)-S2 (residues 336-341)-COOH.
(b) The secondary structure using the CF method:
The a, domain: NH2-S1 (residues 5-15)-S2 (residues 20-30)-S3 (residues 31-
37)-Hl (residues 40-49)-H2 (residues 50-58)-H3 (residues 65-79)-S4 (residues 80-
89)-COOH.
The a, domain: NH2-S1 (residues 94-99)-S2 (residues 106-119)-H1 (residues
122-160)-S3 (residues 161-175)-COOH.
The ou domain: NH2-H1 (residues 178-185)-H2 (residues 186-196)-S1
(residues 197-210)-S2 (residues 211-218)-H3 (residues 226-235)-S3 (residues 240-
250)-S4 (residues 254-264)-S5 (residues 266-273)-COOH.
The TM domain: NH?-S1 (residues 280-310)-COOH.
The C domain: NH2-S1 (residues 333-34l)-COOH.
The hydrophobic region extended between residues 281-307 and there was a




THE PREDICTED SECONDARY STRUCTURE FOR THE HLA-A2
MOLECULE.




























The above predictions, although relying on "peptidestructure" which is an error
prone programme, suggest that the large majority of the bovine sequences in the oq,
(Xj and a3 domains form a-helices or (3-strands at positions similar (bold type) to those
predicted for the HLA-A2 molecule using a more accurate programme (Saper et
al.,1991). In fact, when the HLA-A2 secondary structure was predicted using
"peptidestructure", it was found to be similar to those of the BoLA sequences, and
showed similar deviations from the more accurate secondary structure reported by
Saper and co-workers (1991). It could be argued that the secondary structure of the
BoLA class I molecules is similar to that of HLA molecules and it is therefore likely
that the same applies for their three-dimensional structures. The glycosylation site at
position Asn 86, for both BoLA and HLA molecules was predicted accurately using
the programme "peptidestructure". The transmembrane region was also accurately
predicted. The use of this programme, although useful in determining the structural
similarities between the BoLA and HLA molecules was not sensitive enough with the
present information to determine whether the various BoLA sequences reflected locus
specific structural characteristics.
4.4.3. Comparison of the published BoLA class I sequences in the TM domain:
In the MHCs of humans and mice all the alleles encoded by the same locus
have the same number of amino acid residues in their transmembrane domais (TM).
The only exception to this rule are H-2K molecules, the TM regions of which contain
39 or 40 residues (Ennis et al., 1988).
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The reported BoLA class I sequences show three different groups of TM



















The polymorphic positions in each sequence are highlighted. It is clear that the
sequences containing 35 residues (BL-7, 19.3 and 19.4) all lack two amino acids (T
and G) from the same positions, which are conserved in the other six sequences,
indicating that they are likely to be encoded by the same stretch of DNA. The
sequence KN104, on the other hand, lacks a single amino acid from a different
position. From the above sequences, it is clear, that if the number of amino acid
residues in the TM domain is a specificity of the encoding locus, then the BoLA class
I molecules are encoded by at least three distinct class I loci. These findings are in




5. DISCUSSION AND CONCLUSIONS:
Until very recently the bovine MHC was studied solely by serology. AAS
reacting to polymorphic epitopes, raised by calf/dam reciprocal immunisations are used
to determine the different specificities expressed in a particular animal. Using this
technique it has been generally accepted that the bovine MHC encodes a single highly
polymorphic class I locus (Anon,1982; Bull et al.,1989; Bernoco et al.,1992). This
came from the observation that in most cases each animal could only be identified by
a maximum of two AAS with no evidence of recombination (Bull et al.,1989; Bernoco
et al.,1992).
The use of sensitive techniques such as 1D-IEF, that goes beyond the
resolution of serology, produce complex pictures of the bovine MHC class I encoding
region (Joosten et al.,1988; Oliver et al.,1989). In each case, a multiple band pattern
was produced from individual animals by immunoprecipitating the class I molecules
with MAbs that recognise monomorphic epitopes on the class I molecules.
The aim of this study was to determine biochemically the origins of the
expressed charge heterogeneity observed with 1D-IEF of the class I molecules
obtained from non-stimulated bovine peripheral blood lymphocytes. The study set out
to establish the extent to which different post-translational modifications affect the
observed heterogeneity, and to estimate the number of expressed class I loci in
normal, non-stimulated bovine PBL.
Recent biochemical and molecular biological studies involving the BoLA
system have suggested the presence of two expressed class I loci. Ennis and co-
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workers (1988) reported the primary sequences of two bovine cDNA clones and from
the deduced nucleotide sequences it was suggested that these clones (BL3-6 and BL3-
7) could not be allelic products of the same locus. This finding was based on the
observation that the 3' untranslated regions in humans and mice of alleles from the
same locus show a mean homology of 96+/-2.3%, whereas homology between alleles
of different loci is in the range 74-95%. The 3' untranslated regions of BL3-6
and BL3-7 have a homology of 86.2% which is in the range of alleles of different loci
(Ennis et al.,1988). In another report DNA from an animal expressing the BoLA types
wlO and KN104 was digested with rare cutter enzymes (Sfi I, Mlu I, Not I and Cla
I) and fragments were size separated using field inversion gel electrophoresis (FIGE).
Two cDNA clones (2.1 and 5.1) were isolated from a cDNA library prepared from the
same animal, these two clones showed divergence at the both termini. Hybridisation
with an entire class I cDNA probe revealed multiple fragments generated by each of
the enzymes used. When the 3' untranslated regions of 2.1 and 5.1 were used as
probes, only a single fragment was revealed in each digested sample, showing the
locus specificity of these probes. DNA from transfected mouse L cells, expressing
either KN104 or wlO (Toye et al.,1990), hybridised to the 3' untranslated regions of
clones 2.1 and 5.1, respectively. Northern blot analysis of the mRNA of the two
transfected cell lines provided further evidence that the cDNA clones 2.1 and 5.1 code
for molecules of the BoLA-KN104 and BoLA-wlO serotypes, and they are
representative of two different loci. The long range physical mapping of these genes
using FIGE analysis of DNA from homozygous as well as heterozygous animals
revealed that they are separated by not more than 210kb (Bensaid et al.,1991a).
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Bensaid and co-workers (1991b) also reported that the rare-cutter enzyme Sfi I cleaves
the DNA from an animal which is serologically typed as wl0/KN104 into six
fragments. As it was assumed that each BoLA class I gene measures 5kb, and that the
probability of there being an Sfi I site in any given 5kb piece of DNA is low, it is
probable that every Sfi I fragment contains at least one class I gene, this is
exemplified by the finding that two distinct, 3' untranslated regions are transcribed by
the same Sfi I fragment of 250kb (Bensaid et al., 1991a). Thus there is the possibility
of the presence of at least seven BoLA class I loci (Bensaid et al.,1991b). Further
evidence for the presence of at least two class I BoLA loci came from the use of the
polymerase chain reaction to amplify cDNA from expressed bovine MHC class I
genes. Sequences obtained from transmembrane and cytoplasmic domains were used
to identify the number of expressed alleles. The results suggested the presence of four
alleles representing the products of two (or more) class I loci. The data obtained also
suggested the presence of alternatively spliced mRNA which results in the removal
of exon 7, predicting a truncated molecule with the cytoplasmic portion 16 amino
acids shorter than usual (Ellis et al., 1993). It must be emphasised that the experiments
described by Ellis and co-workers involved the use of Theileria annulata transformed
peripheral blood mononuclear cells. Such activated cells have been shown to express
activation-associated class I molecules which are not present on normal cells. The
amino acid backbones of such molecules were shown to exhibit a wide range of
molecular masses (Mr) including Mr of approximately 37,000, which is 2,000-3,000
less than the estimated M, of the amino acid backbones of normal class I molecules
(Bensaid et al.,1989). This size heterogeneity observed by Bensaid and coworkers
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(1989) could reflect the expression of alternatively spliced class I molecules as
described by Ellis and co-workers (1993). Ulker and co-workers (1990) reported that
concanavalin A activated T cells express almost exclusively alternatively spliced forms
of the class lb molecule Qa-2.
Biochemical evidence for the expression of two expressed BoLA class I loci
came from studies carried out by Joosten and co-workers (1992). In these experiments
a polymorphic monoclonal antibody (IL-A31), raised against a molecule of an African
wlO specificity, recognised a product that was distinct from other wlO associated
molecules precipitated with W6/32 as was revealed by peptide mapping using the
endoprotease V8. Therefore it was concluded that the serologically defined wlO
serotype encodes at least two independent class I locus products expressed on normal
bovine PBM (Joosten et al., 1992).
5.1. THE EXPRESSED BOVINE CLASS I MOLECULES:
SDS-PAGE analysis of the immunoprecipitates revealed that all MAbs
recognised a doublet with heavy and light variants at 43,000-44,000 and 39,000-40,000
respectively (Fig. 4.1), Both variants were sensitive to neuraminidase treatment
indicating that they have transversed the trans-Golgi network. Their presence in the
detergent phase indicated that they still retain their hydrophobic regions suggesting
that they are membrane bound. The molecules exhibiting the molecular mass between
43,000-44,000 are most likely to represent mature class I molecules. The lighter
molecules are artifacts of the immunoprecipitation procedure. This was confirmed by
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the use of protease inhibitors in the lysis buffer which lead to a dramatic reduction in
the presence of such molecules (Fig. 4.8a). The complexity of the 1D-IEF patterns
obtained from samples treated with protease inhibitors using MAb W6/32 was
unchanged (Fig. 4.8b). This indicated that the presence of the light molecular mass
variants in samples not treated with protease inhibitors did not contribute significantly
to the observed charge heterogeneity and that other factors were exerting their
influence. The results from the 2D SDS-PAGE analysis give support to this suggestion
by revealing that most, although not all, the charge variants observed on the first
dimension subsequently separate into heavy and light molecular mass variants on the
second dimension. The reason for the light molecular mass variants retaining the same
charge as their parent molecules could be explained by inspecting the five published
class I sequences (Ennis et al.,1988; Brown et al., 1989 and Bensaid et al.,1991). In all
these class I sequences, the cytoplasmic tail, which is the most likely part of the
molecule to be digested, harbours equal numbers of positively and negatively charged
residues. Therefore, it could be envisaged that the removal of this part of the molecule
would not interfere with the overall charge of the remaining sequence. Both parent and
truncated molecules, therefore, could be expected to have the same charge on 1D-IEF.
On the other hand, the finding that both heavy and light variants retain the same pi
point could reflect the possibility that the cytoplasmic regions of the class I molecules
in our samples do not have any charged residues. Therefore, the proteolytic removal
of the corresponding sequence would not have any effect on the electrophoretic
migration of the rest of the molecule.
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The 1D-IEF patterns produced by IL-A88 was different from that produced by
W6/32 and B1.1G6 in that it revealed the presence of more basic molecules (IL-A88+
in fig. 4.3). Sequential immunoprecipitation experiments revealed that the size of the
IL-A88+ molecules is approximately 39,000 (Fig. 4.4a). The inability of MAbs W6/32
and B1.1G6 to precipitate similar molecules could be given a number of explanations.
The IL-A88+ molecules might not be associated with (32m which is required for
recognition by W6/32 and B1.1G6 or, on the other hand, they could simply lack the
appropriate epitope whether on the heavy (W6/32) or light chain (B1.1G6). Heavy
chains that lack the association with p2m are more prone to proteolytic digestion
(Ploegh et ah,1979; Kissonerghis et ah,1980) which would explain the smaller sizes
of the IL-A88+ molecules. Such molecules also show transient expression at the cell
surface (Ortiz-Navarrete and Hammerling,1991; Rocket ah,1991) which would explain
the poor reproducibility of the IL-A88+ pattern. The combination of observations of
the lower molecular mass, the inability to be recognised by MAbs W6/32 and B1.1G6
and the poor reproducibility of the more basic pattern with IL-A88 itself, could be a
reflection of the fact that these molecules are class I heavy chains that escaped
association with f^m during biosynthesis, or have dissociated from it at the cell
surface. The existence of such products has been reported in other species (Rock et
al.,1991; Vitiello et ah,1990; Hanson et ah,1988). Until recently, such surface
expressed heavy chains were thought to be functionless. However, Glas and co¬
workers (1992) suggested that allospecific and restricted CD8+ T cells capable of
killing P2m-deficient cells could be generated, indicating that surface expressed naked
heavy chains can act as antigen or antigen presenting molecules.
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It must be emphsised at this point that the IL-A88+ molecules could also be
non-MHC class I molecules that co-precipitate when the MAb IL-A88 is used.
5.2. EFFECTS OF POST-TRANSLATIONAL MODIFICATIONS ON BoLA
HETEROGENEITY:
The charge heterogeneity of BoLA class I molecules observed by 1D-IEF could
have resulted from the differential modification of a small number of polypeptides.
Two post-translational modifications (glycosylation and phosphorylation) and of one
post-transcriptional modification (alternative splicing of pre-mRNA) that might lead
to the same gene product having different charges have been reported to occur in class
I molecules. The effects of these modifications were studied by the use of enzymatic
digestion, differential radioactive labelling with 32Pj and 35S methionine, and analysis
by SDS-PAGE, 1D-IEF and 2D electrophoresis.
The sialic acids are a diverse family of 9-carbon carboxylated sugars usually
found as terminal monosaccharides of animal oligosaccharides. The most common
sialic acid is N-acetyl-neuraminic acid which is thought to be the precursor of all
modified forms of the sugar many of which exist in ungulates (Varki,1992). The
nature of the sialic acid attached to bovine MHC molecules is unknown. However, the
use of neuraminidase from Vibrio cholerae reduces the heterogeneity of the 1D-IEF
patterns (Fig. 4.4b). The treatment also has an effect on the migration of these
molecules in SDS-PAGE. This type of neuraminidase hydrolyses O-ketosidic a2-3,
a2-4, a2-6 and a2-8 bonds of terminal N-acetylneuraminic acids. Methods using this
enzyme were developed in this laboratory in conjunction with Joosten and co-workers
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and has been shown to completely desialate bovine MHC class I molecules (Joosten
et al.,1988). Some types of sialic acids (4-O-acetylated sialic acids) are resistant to all
known sialidases (Schauer,1987), however, there is no published evidence to date that
suggests the presence of these sugars on MHC molecules.
The differential sialation of a single class I polypeptide could result in it
having different mobilities on 1D-IEF, thus contributing to the observed heterogeneity.
SDS-PAGE analysis of the neuraminidase treated samples revealed a shift in mobility
that corresponds to a 1,000-1,500 change in molecular mass (Fig. 4.5). The size of the
shift indicates that the BoLA class I molecules carry up to 3 sialic acid residues. The
1D-IEF analysis of these samples revealed that the treatment with neuraminidase
reduces the observed charge heterogeneity and causes a shift to more basic pi points
indicating the loss of a negative charge which we attribute to the loss of sialic acid
residues (Fig. 4.4b). When the samples were treated with EndoF the shift was larger
and reflected a decrease in molecular mass of about 4,000 (Fig. 4.5). These results
indicate that the class I molecules have a single N-linked glycosylation site that is
occupied by a complex sugar molecule. It was also observed that the heavy and light
molecular mass variants were still present after digestion with both enzymes,
suggesting that the lighter molecules in the pattern are actually fully glycosylated and
that their lower molecular masses are not a reflection of incomplete glycosylation.
This gives further support to the idea of them being heavy chains that have undergone
proteolytic digestion at or near the cell surface. The 1D-IEF patterns of EndoF treated
samples were similar to those obtained after neuraminidase treatment alone (Fig. 4.6)
giving further support to the notion that the presence of sialic acids is the major
144
contributor to charge heterogeneity and that the digestion with neuraminidase from V.
cholerae removes all heterogeneity arising from sialic acid. The findings also indicate
that the BoLA class I molecules are unlikely to carry any O-linked glycosylation sites
due to the fact that the molecular mass calculated for the naked amino acid backbones
of the published class I sequences were approximately 40,000 (Ennis et al., 1988;
Brown et ah,1989 and Bensaid et ah,1991). This, when taken together with the
molecular mass contributed by the N-linked sugar molecule (4,000), would give an
approximate molecular mass of 44,000 which is that of a mature class I molecule.
It must be noted at this point that the shifts observed with SDS-PAGE and 1D-
IEF of samples treated with neuraminidase and EndoF are unlikely to be the products
of contaminating protease activity. This stems from the fact that there was no evidence
of non-specific digestion which is expected if there was active protease digestion.
Furthermor, the enzymes used were of high purity and that any protease activity that
could have been present was below the limits of detection as is specified by the
manufacturers. However, the buffers used did not include any protease inhibitors and
although proteolytic digestion is highly unlikely as was seen by 2D analysis and it
could not be dismissed completely.
The class I molecules also carry phosphorylation sites at serine residues in the
cytoplasmic tail of the molecule (Ellis et al.,1993). Phosphorylated class I molecules
may exhibit a more acidic pi than non-phosphorylated molecules, therefore, the
differential phosphorylation of a small number of amino acid backbones could be
responsible for the observed 1D-IEF heterogeneity (Loube et al.,1983).
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In order to investigate these options two approaches were used. In the first,
non-stimulated PBM were labelled with either 35S methionine or 32Pj. The cells were
then lysed in a buffer containing both phosphatase and protease inhibitors and the
class I molecules were immunoprecipitated in the usual manner. The SDS-PAGE and
1D-IEF analysis of the samples revealed that it was only the molecules labelled with
35S methionine that were observed with no trace of any phosphorylated molecules
(Figs. 4.8a,b). To determine whether the cells had actually taken up 32Pi5 total lysate
of phosphorylated cells was analysed using SDS-PAGE. It was clear that a number of
proteins in the molecular mass range of 20,000-80,000 were phosphorylated (Fig. 4.7).
The second approach was an indirect one, in which, 35S methionine labelled,
neuraminidase treated class I molecules were further treated with the enzyme potato
acid phosphatase (PAP). The rationale was that treatment with PAP should remove
any phosphate residues from the amino acid backbone and that this will result in shifts
in the electrophoretic mobility and subsequent reduction in the complexity of the
patterns observed. Results from both SDS-PAGE and 1D-IEF (Figs. 4.9 and 4.10
respectively) revealed that none of the class I molecules in the pattern were affected
by this treatment, and that the complexity of the 1D-IEF pattern remained identical
to that obtained after neuraminidase treatment alone. These observations when taken
in combination strongly suggest that the BoLA class I molecules immunoprecipitated
from the membranes of resting cells are not phosphorylated. Similar finding have been
reported for HLA class I molecules (Loube et al.,1983; Eichholtz et al.,1992).
Therefore, the charge heterogeneity observed is not explained by differential
phosphorylation events.
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Another mechanism that could result in different isoforms of a single molecule
is the alternative splicing of pre-mRNA. Alternative splicing is a post-transcriptional
modification that could occur in almost every exon. However, pre-mRNA splices have
been rarely shown to occur at the 5' end of the encoding RNA and even when such
splice products have been found no corresponding protein was present (Lalanne et
ah,1985 and Trancy et al.,1984). This form of alternative splicing could add to the
diversity of class I molecules and increase the repertoire of antigenic peptides that
could be presented (Transy et al.,1984 and Lalanne et al.,1985). However, all the
detected proteins that are generated by alternative splicing arise from the 3' end of the
pre-mRNA and not the 5' portion. Further, in all the reported cases of alternatively
spliced class I molecules the result is an amino acid backbone that is either shorter or
longer than the wild type protein. Furthermore, the expression of the alternatively
spliced molecules is equal to only 10% of that of the wild type protein (Archibald et
al.,1986; Lew et al.,1986; McLuskey et al.,1986; Rogers et ah,1986; Krangel et
al.,1986; Vogel et al.,1989; Cianetti et ah,1989; Grossberger et ah,1990; Ishitani et
ah,1992 and Ellis et ah, 1993). Ulker and co-workers (1990) reported that the canonical
mRNA encoding the membrane bound form of the class lb molecule Qa-2
predominated in non-stimulated mouse tissues but the cultured cell lines express
enhanced levels of the truncated mRNA. In fact, in some cell lines almost all the
expressed Qa-2 was produced by alternative splicing. Alternative splicing was also
reported to exist the BoLA system, where cells transformed with the parasite Theileria
annulata showed truncated class I molecules missing 16 a.a. from their cytoplasmic
domain (Ellis et ah, 1993). Therefore, it seems that alternative splicing could be a
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mechanism induced by culturing and/or activation of the cells.
The biological function of the reported alternatively spliced class I molecules
is yet undetermined and remains a matter of speculation. Due to the fact that most
alterative splice events occur at the 3' end of the pre-mRNA it could reflect a certain
function for the cytoplasmic domain of the molecule (Ellis et al.,1990). Additionally,
structural variation within the intracellular sequences of class I molecules may lead
to different pathways of intracellular processing (Zuniga and Hood, 1986). A further
result of alternative splicing could be the generation of soluble forms of class I
molecules. However, the biological significance of such forms is debatable (Krangel
et al.,1986). The form of alternative splicing that is most likely to have a functional
importance is the deletion of exon 7 which encodes the phosphorylation site
(McLuskey et al.,1986; Ellis et al.,1993). The phosphorylation of class I molecules
may indicate a role in receptor signalling. The apparent physical interaction of MHC
class I molecules with insulin receptors and other hormones (Fehlmann et al., 1985;
Phillips et al.,1986 and Edidin,1986), may implicate them in the transduction of
hormone receptor-mediated signalling.
The possibility that the heterogeneity observed with the 1D-IEF patterns of the
BoLA molecules was a result of alternative splicing, was assessed indirectly. Due to
the fact that alternatively spliced molecules show differences in size it was reasoned
that their expression could, therefore, be verified using a combination of 1D-IEF and
SDS-PAGE in 2D electrophoretic analysis. Reported that alternatively spliced BoLA
molecules, isolated from Theileria annulata transformed cells, lack 16 residues from
their cytoplasmic domain, a change in size that is equivalent to a molecular mass
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change of just over 2,000. Such a change in molecular mass could be resolved by our
2D system. The results obtained from the 2D analysis of neuraminidase treated BoLA
class I molecules reflected the presence of a number of charge variants that exhibited
identical molecular masses (Fig. 4.12). Some variants revealed the usual doublet
formation, others revealed a single heavy band of approximately 44,000 in molecular
mass. These results indicated that if alternative splicing does occur in the BoLA
system it must result in isoforms of identical sizes and that, unlike alternative splicing
reported in species such as humans, mice and sheep, the alternative splicing in the
BoLA system is the major contributor to the heterogeneity observed. This is unlikely
to be the case. We therefore, conclude that the complexity of the 1D-IEF patterns
obtained from non-activated, non-cultured bovine PBL is not a result of alternative
splicing of pre-mRNA.
5.3. THE EXPRESSED BoLA MOLECULES ARE PRODUCTS OF SEPARATE
LOCI:
From the results discussed in the previous section it is clear that the observed
1D-IEF heterogeneity for BoLA class I molecules is not a product of post-translational
modifications and is unlikely to be the product of post-transcriptional modifications.
Charge heterogeneity could also reflect differences in the primary sequences
of the molecules observed. The use of peptide mapping in the second dimension as
a means for differentiating among molecules with different primary sequences was
used to investigate whether this was the case with the observed charge variants of the
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BoLA system. The results indicated that each of the charge variants has a unique
digestion pattern with endoproteinase Glu-C (Figs. 4.13, 4.14 and 4.15). The molecule
vl obtained from two animals with the wlO serotype (Figs. 4.13 and 4.15) has an
identical isoelectric point and digestion pattern to a molecule precipitated from an
animal exhibiting wlO in another study reported by Joosten and co-workers (1992).
This molecule was precipitated using the polymorphic monoclonal antibody IL-A31
raised against a determinant on a wlO associated molecule. We propose that the
molecules vl, reported here, and IL-A31 (Joosten et al., 1992) are identical.
Furthermore, molecules v3 and v5 (fig. 4.14) and v3 and v4 (fig. 4.15) could also be
identical given the identity of their digestion patterns and pi points and from the fact
that the animals exhibiting them share the specificity wl7. Further, some molecules
immunoprecipitated from the same animal exhibited identical digestion patterns (v3
and v5, fig. 4.14 and v3 and v4, Fig. 4.15). Such similarity could be expected between
related molecules from the same species especially when taking into account the fact
that even the class I molecules of different species share a great deal of similarity. For
example, BL-6 has 73-78% homology to HLA-A,B and C sequences and BL-7 has 75-
82% homology to HLA-A,B and C molecules (Ennis et ah, 1988).
It was also observed that animals sharing the serological type wlO share a
number of different charge variants with different digestion patterns, such patterns
were seen with immunoprecipitations from cells of other animals exhibiting the w 10
serotype (Figs. 4.13 and 4.15). Similar findings were observed for animals sharing the
wl7 serotype (Figs. 4.14 and 4.15). These results indicate that each serologically
defined BoLA specificity consists of a number of component antigens that differ
150
amongst each other in their primary sequences. It follows from these finding that the
allo-antisera defining each serological specificity do not identify individual antigens
as is proposed by Bull and co-workers (1989) and Bernoco and co-workers (1992) (are
not monospecific). Furthermore, it was observed that the serotypic patterns remained
unchanged between animals sharing it, indicating that the component molecules are
encoded by alleles that exist in linkage disequilibrium. The number of different charge
variants with different digestion patterns observed in individual animals (figs. 4.13,
4.14 and 4.15) suggests that BoLA class I region encodes at least 3 distinct loci.
5.4. THE EXPRESSION PATTERN OF BoLA CLASS I MOLECULES:
The visual comparison of the BoLA 1D-IEF patterns indicates that animals
with similar serological types share very similar banding patterns (Figs. 4.16, 4.17 and
4.18). these patterns could be dissected and the various molecules allocated to
different serological specificities. Although the majority of different charge variants
could be allocated to serological specificities with which they invariably appear, other
molecules appeared to be inconsistent in their associations with the various serological
specificities. Such molecules exhibit association with a certain serological specificity
in some animals but not in others ( "?" in Figs. 4.16, 4.18, 4.19 and 4.20). These
results indicate that the BoLA class I molecules show strong linkage disequilibrium,
however, this linkage is not absolute. It further indicates the expression of more than
one class I locus.
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The results from immunoprecipitation experiments using W6/32 and the allo-
antisera further supported the above findings and gave further indication to the
complexity of the BoLA class I region. The molecules recognised by either MAb or
allo-antisera display a number of features that make them likely to be the products of
a small number of expressed loci. Molecules '10b' and 'lib' (Fig. 4.19) were
recognised by either the allo-antiserum or the MAb, not both. The affinity of the
different allo-antisera towards these molecules was also different. Allo-antiserum 69
reacted more strongly to the 'b' molecules than it did to those seen by W6/32. Allo-
antiserum 102, on the other hand, exhibited a weaker reaction to the basic molecules
while reacting strongly with the molecules recognised by W6/32. In addition the bands
revealed by AAS 69 and 102 (Fig. 4.19) together could not account for all the IEF
bands revealed by W6/32. Immunoprecipitations using AAS 66, 97 and 100 each
recognised up to five different charge variants (Fig. 4.20a,b). These, unlike the
molecules precipitated with AAS 69 and 102, were all recognised by W6/32.
Furthermore, in this case it was the monoclonal W6/32 that recognised molecules with
more basic pi points, that were not recognised by any of the AAS (18b and 17b, Fig.
4.20). These discrepancies between W6/32 and the AAS suggest the expression of
more than one class I locus.
The 1D-IEF patterns produced by W6/32 and/or the AAS are reproducible
among animals with identical serotypes in the population of animals studied. This
suggests the presence of linkage disequilibrium among the different class I loci in the
herd. The limited breeding pool maintained by artificial insemination also plays a role
in limiting the number of different serological specificities present in our population,
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which would exaggerate the effect of any linkage disequilibrium.
To extend the panel of AAS and improve the ability to distinguish between the
products of different BoLA class I loci it may be advantageous to use reciprocal
immunisations between animals from genetically distant breeds (Bos taurus and Bos
idicus). It is also advantageous to use the results of 1D-IEF typing in future
immunisations to refine the available panel of AAS.
5.5. THE BOVINE CLASS I cDNA SEQUENCES: STRUCTURAL ANALYSIS.
The use of the GCG programme "Isoelectric" revealed that the bovine class I
molecules have pi points that, as expected, fall within the pH range 5-7. BL-6 and
BL-7 (Ennis et al.,1988) had pi points of 5.24 and 5.27 respectively (Fig. 4.26). The
sequences KN104 and wlO (Bensaid et al.,1991) had pi points of 5.71 and 6.11
respectively (Fig. 4.28). The higher pi shown by wlO is consistant with the observed
migration of wlO associated molecules on 1D-IEF (Figs. 4.16 and 4.19). pBoLA-1
(Brown et al., 1989) had a pi value of 5.74 (Fig. 4.27). These values are calculated for
the amino acid backbones alone. Although, it is accepted that in general the class I
MHC molecules encoded by different loci cover, on the whole, different ranges of pi
points (Yang et al., 1984), overlap is still observed. The results obtained here confirm
this and show that bovine class I molecules encoded by different loci, as is expected
with BL-6 and BL-7 (Ennis et al.,1988), could have very similar pi values (5.24 and
5.27, respectively).
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The use of the programme "peptidestructure" to predict the secondary structure
of the available class I sequences revealed that they were in agreement with the
predicted structure ofHLA-A2 using the same programme. However, "peptidestructure"
relies on the CF and GOR (Chou and Fasman,1978 and Gamier et al.,1978,
respectively) algorithms which are only 50-60% accurate (Argos,1989). Nevertheless,
the fact that the use of the same programme to predict the secondary structure of the
HLA-A2 molecule gave a result resembling that obtained for the BoLA sequences
indicated that the class I molecules in human and cattle have an identical overall
three-dimensional structure (Figs. 4.29-4.34). It, must be stressed, however, that minor
deviations will exist as was observed for the HLA and H-2 three-dimensional
structures (Bjorkman et al.,1987; Zhang et al., 1992). It should emphasised that the use
of this programme with the current sequence data is inadequate to expose any locus
specific differences in the secondary structures of the BoLA molecules.
It has been reported that with the exception of H-2K molecules, the
transmembrane regions of alleles of the same locus in the HLA and H-2 system have
an equal number of residues (Ennis et al.,1988). The inspection of the published
transmembrane region sequences for class I BoLA molecules indicates the presence
of alleles of three different loci. BL-6 (Ennis et al.,1988), pBoLA-1 (Brown et
al.,1989), wlO (Bensaid et al.,1991) and D19.1 and D19.2 (Ellis et al.,1993) all have
37 residues in their transmembrane regions. BL-7 (Ennis et al.,1988) and D19.3 and
D19.4 (Ellis et al.,1993) all have 35 residues. KN104 (Bensaid et al.,1991), on the
other hand, has 36 residues in the transmembrane region.
5.6. CONCLUSIONS;
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From the results presented in this thesis the following could be concluded. The
BoLA class I molecules on non-stimulated bovine PBL obtained from Bos taurus
animals are glycosylated at a single N-linked position (Asn 86) and that the sugar
moiety is of the complex type with up to three terminal sialic acid residues. It further
appears that the class I molecules on such cells are not phosphorylated. Furthermore,
both glycosylation and phosphorylation are responsible for the observed charge
heterogeneity observed on 1D-IEF. The results also suggest that alternative splicing
of pre-mRNA is unlikely to generate the 1D-IEF heterogeneity of BoLA class I
molecules immunoprecipitated from non-stimulated, non-cultured bovine PBL.
The use of peptide mapping reveals that the molecules observed using 1D-IEF
have differences in their primary sequences. The number of different charge variants
with different digestion patterns suggests the presence of at least three class I encoding
loci. The peptide maps further reveal the existence of linkage disequilibrium in the
BoLA class I region.
The visual comparisons of the 1D-IEF patterns of different animals and the use
of the different bovine AAS in the immunoprecipitation of class I molecules further
support the existence of linkage disequilibrium and augment the notion of the
expression of a number of different class I loci. The tight linkage reported above may
explain the inability of the allo-antisera to distinguish between individual antigens in
microcytotoxicity assays and is likely to obscure the presence of the less polymorphic
molecules.
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The results from the computer analysis of the available BoLA cDNA sequences
indicate that bovine class I molecules possess pi values similar to those of MHC
systems of other species (pH range 5-7). Additionally, the comparison of the
secondary structures of the BoLA sequences and that of the HLA-A2 molecule,
suggests that the three-dimensional structure of bovine class I molecules is similar to
that of molecules from the HLA and H-2 systems. Furthermore, the sequences of the
transmembrane regions of the BoLA cDNA sequences further confirm the results from
the biochemical studies described above which indicate the presence of at least three
class I loci.
The findings of this project have established a number of facts that could be
used in future and existing work in the BoLA area. It is clear that each BoLA
serological type is in fact composed of a number of different molecules encoded by
more than one locus and does not define variants of the same molecule. Therefore, the
assignment of serological specificities to the "BoLA-A" locus is premature.
Furthermore, it appears that the allelic products of the BoLA loci exhibit strong
linkage disequilibrium. This and other information from 1D-IEF typing should be
taken into account and used to refine the specificity of the available panel of AAS so
that they could truly be "operationally monospecific". Such reagents could then be
used with more confidence in studying the associations of BoLA molecules with
various diseases and production characteristics for selection purposes.
Further efforts should also be given to the identification of the allelic products
of the different BoLA loci both on the DNA and the protein level. The system of
peptide mapping used here is reproducible and could be refined further for the detailed
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biochemical characterisation of individual BoLA polypeptides. This work is only the
first step towards understanding the individual characteristics of these molecules which
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All animals used in these experiments are British Friesians from the Blyth
Bank herd and have been serologically typed.
A.1.2. MOUSE MONOCLONAL ANTIBODIES (MAb):
The MAbs used were W6/32 (Serotec), IL-A88, IL-A30, IL-A60, IL-A73 (kind
gift from ILRAD) and B1.1G6 (Kind gift from Dr.B.Mallison). The specificities
of all the MAb used are given in the table below.
Antibody Specificity




IL-A88 Anti BoLA-class I,
monomorphic,
non-conformational.
IL-A30 Anti bovine IgM.
IL-A60 Anti bovine IgG^
IL-A73 Anti bovine IgG2.
B1.1G6 Anti human p2m,
cross reacts with bovine
p2m.
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Note: The negative control MAb 4E (anti-HLA-B) has the same isotype as W6/32
(IgG^) and was a kind gift from Dr.S.Y.Yang.
A.1.3. ALLQ-ANTISERA (AAS):
All the ASS were produced from calf-dam reciprocal immunisations. A list of
the Edinburgh AAS is given in table A.l on page 220.
A.1.4. RECIPES FOR SDS-POLY ACRYLAMIDE GEL ELECTROPHORESIS
(SDS-PAGE):
A) Stock Acrylamide:BIS (30%T, 2.67%C):
29.2g Acrylamide (Sigma).
0.8g N'N'-Bis Methylene Acrylamide (Sigma).
Make up to 100ml with DH20.
B) 1.5M Tris-Cl, pH 8.8:
45.41g Tris base or Trizma (Sigma).
50ml DHzO
Adjust pH to 8.8 with HC1 (Fisons)
Top up to 250ml with DHzO.
C) 1M Tris-Cl, pH 6.8:
24.22g Tris base.
50ml DHzO
Adjust pH to 6.8 with HC1
Top up to 200ml with DH2Q.
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D) SDS sample buffer:
2% Sodium Lauryl Sulphate or SDS (0.8g) (Fisons).
20% glycerol (8ml) (Fisons).
0.125M Tris pH 6.8 (5ml of 1M solution or 0.6g Tris base)
0.004% Bromophenolblue (BDH).
5% 2-Mercaptoethanol (2ml) (Sigma),





make up to 1L with DHzO.
F) Running gel solutions:
The following recipes are enough for 2 mini SDS gels used with the mini Protein
II system (BIORAD):
12% (ml) 15% (ml)
DH20 3.35 2.36
1.5M Tris-Cl (pH 8.8) 2.5 2.5
10% SDS solution 0.1 0.1
Acrylamide:bis 4 4.99
10% APS (Sigma) 0.05 0.05
TEMED (Sigma) 0.005 0.005
The above proportions could be manipulated according to the size of the gel needed.
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G) Stacking gel solutions:
The following recipes are enough for 2 mini SDS stack gels used with the mini
Protein II system (volumes given in ml):
DH20 6.2
1M Tris-Cl (pH 6.8) 1.25




The proportions could be manipulated according to the size of the gel needed.
A.1.5. RECIPES FOR ISOELECTRIC FOCUSING (IEF):
A) Acrylamide:Bis (30%T, 5.33%C):
28.4g Acrylamide.
1.6g N'N'-bis methylene acrylamide.
Make up to 100ml with DHzO.
B) TX114 Lysis buffer:
0.5ml TX114 (Fluka).
10ml 0.5M Tris-Cl pH 7.4 (50mM).
0.5ml 1M MgCl2(5mM) (Fisons).
Make up to 100ml with DH20.
C) TX114 Lysis buffer with inhibitors:













lOmM Tris-acetate pH 7.4.
make up to 100ml with DH20.
C) NET buffer solution:
10ml 0.5M tris-Cl pH 7.4 (50mM).
0.5ml 10% Nonidet P40 or NP40 (Fisons).
10ml 1.5M NaCl (150mM).
0.5ml 1M EDTA (5mM) or (1ml 0.5M).







Leave in 37C water bath until urea dissolves.
Add ampholines (Pharmacia LKB):
2.2ml pH range 5-7.
0.55ml pH range 3.5-10.
0.22ml pH range 7-9.
Mix well then add:
lOOul Ammonium Persulphate.
50ul TEMED.
For mini rod gels (complimentary to the mini Protein II system) use same solutions
as above but only 1/10 of the volume.
E) IEF sample buffer:
28.5g Urea.
lml Ampholine pH range 3.5-10.
lml 10% NP40.
2.5ml Beta-mercaptoethanol
Make up to 50ml with DHzO and store at -20C in lml aliqouts.
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F) Overlay buffer:
1 part IEF buffer.
3 parts DH20.
0.1% Bromophenolblue.
G) Top tank buffer:
100ml 0.5M NaOH (Fisons).
Make up to 1L with DH20.
H) Bottom tank buffer:
2.2ml commercial H3P04 (Fisons).
Make up to 1L with DH20.
I) Apparatus:
Teflon inserts and Aculon spacers.




a.1.6. 2-dimensiqnal gel electrophoresis (2d):
Use 12% SDS-PAGE and IEF recipes as above. The apparatus used is the Mini 2D
cell (BIORAD).
A) 2D equilibration buffer:
0.125 Tris base (0.76g).
10% glycerol (lOg).
2.3% SDS (2.3g).
Make up to 50ml with DH20, adjust pH to 6.8 with HC1 then top up to 100 with
dh2o.
a.1.7. 2d peptide mapping:
Use 15% SDS-PAGE and IEF recipes as above. The apparatus used is the Mini 2D
cell (BIORAD).
A) V8 Protease from Staphylococcus aureus EC 3.4.21.19 (Bohringer Mannheim)
made up to a concentration of 0.25mg/ml in 0.125M Tris-Cl pH 6.8 and frozen at -
20C as 200ul aliqouts (62.5ug each, 2ul are used for each run).
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B) V8 Protease dilution buffer:







C) 1% Agarose solution (BRL).
A.1.8. FACS TEST SOLUTIONS:
A) Fluorescent Immunoconjugate (Nordic Laboratories):
i. For MAbs:
Rabbit anti mouse Ig (1/100).
ii. For sera:
Rabbit anti bovine Ig (1/100).









0.4ml Sodium Heparin (5000U/ml) (Leo Laboratories Ltd.)
in 900ml of DHzO and pH to 7 with sodium carbonate (Gibco) then top up to 1L
with DH20.
B) Ficoll/Hypaque s.g. 1.069:
67.5g Ficoll (Pharmacia LKB) dissolved in 400ml of hot DH20 then make up to
750ml and leave to cool.
79.8g Sodium Hypaque (Stirling Research) and dissolve in 120ml of warm DHzO
then make up to 200ml and leave to cool.
Add the Sodium Hypaque to the Ficoll solution gradually, stirring all the time until
s.g. 1.069 is achieved.
C) 14Carbon Labelled Low Molecular Weight Markers (Sigma).
D) 35Sulpher Labelled Methionine (Amersham). Usually in 66ul that is diluted to final
volume of 200ul with ImM 2-Mercaptoethanol.
E) 32Pj carrier free phosphorus (Amersham).
F) Pansorbin cells (Protein A) (Calbiochem).
G) Gamma-bind G agarose, recombinant form of protein G (BDH). Switched to
Gamma-bind G sepharose (same product as above but from Pharmacia LKB).
H) Neuraminidase from Vibrio cholerae EC 3.2.1.18 (Behring), 0.1 unit used for each
digestion as prepared by manufacturer.
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I) Endoglycosidase F/N-Glycosidase F from Flavobacterium meningosepticum
EC 3.2.1.96/EC 3.2.2.18. (Bohringer Mannheim).
J) Deglycosylation buffer:





The buffer is added to the enzyme to make a final volume of 50ul.
K) Potato acid phosphatase EC 3.1.3.2 (Calbiochem).
L) Dephosphorylation buffer:
50mM 2-(N-Morpholino)ethanesulphonic acid (MES) pH 6.2 (BDH).
0.1% NP40.
The buffer is added to the enzyme to make a final volume of 200ul.
M) Commercial Dimethyle Sulphoxide (DMSO) (Fisons).
N) PPO/DMSO:
lOOg 2,5-Diphenyl-Oxazole or PPO (Sigma).
400ml DMSO.
O) Kodak X-OMAT AR X-ray film.
P) Electrophoresis Power supply:
i. Pharmacia LKB constant power supply ECPS 3000/150.
ii. LKB Bromma 2301 Microdrive 1 power supply.
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Q) Centrifuges:
i. IEC Centra-8, Refrigerated and Unrefrigerated.
ii. Sorvall RC-5B Refrigerated Superspeed Centrifuge.
iii. Eppendorf 5415.
iv. Sarstedt MH-2K (refrigerated).
APPENDIX 2: FACS ANALYSIS OF BOVINE AAS.
It was observed some bovine AAS were unable to immunoprecipitate class I
for 1D-IEF analysis, although they showed positive reactions in
lymphomicrocytotoxicity assays. The most likely reason for this observation was that
the non-reacting sera had a small proportion of IgG (products of a primary challenge).
In order to investigate this possibility, bovine T cell lines transformed by the parasite
T. annulata were used to eliminate the possibility of the AAS reacting to surface
expressed Ig. The cells were initially incubated the AAS to be tested, followed by a
MAb directed against bovine IgM (IL-A30), bovine IgGj (EL-A60) or IgG2 (IL-A73).
The final step involves the addition of the fluorescent conjugate. The results are shown
in figures A.l and A.2, and confirmed that the successful sera had higher proportions
of IgG than unsuccessful sera. The sera production records further confirmed that the




ISOTYPE PROPORTION TEST FOR THE SUCCESSFUL
IMMUNOPRECIPITATING AAS 66 AND 102.
Figure A.la, shows the FACS profile for the AAS 66 (w6 broad specificity).
Figure A.lb shows the profile obtained with AAS 102 (wll specific). In both cases the
proportions of IgG, and IgG2 are higher than those observed for IgM and the which






ISQTYPE PROPORTION TEST FOR THE NON-
IMMUNOPRECIPITATING AAS 10 AND 86.
Figure A.2a, shows the FACS profile for the AAS 10 (w6 broad specificity). Figure
A.2b shows the profile for AAS 86 (wl8 specific). In both cases the relative





Table A.l: EDINBURGH ALLO-ANTISERA AND THEIR DEFINED
SEROLOGICAL SPECIFICITIES.
SPECIFICITY DEFINING SERA ASSOCIATED SERA
wl 1, 8, 83, 151 112




w6 9, 10, 66, 75, 97
w7 11, 17, 67, 68
w8 13
w9 14, 140
wl 0 69, 71
wl 1 73, 76, 102, 110
wl2 47, 133
wl3 5
wl4 80, 138 16, 136, 101, 109, 136
wl5 105, 152
wl 6 38, 43, 114, 131
wl 7 12, 92, 93
wl 8 81, 86, 113
wl 9 100
w2 0 78, 121




w32 40, 124, 126
Eu27 94
Unknown 30, 85 (w4, w7 and
wl0) *, 87 (w3) *,
89, 91, 99, 104,
116, 118, 127, 137
*
Possible specificities defined.
